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ABSTRACT 
CANCER CHEMOPREVENTION BY DIETARY COMPOUNDS TARGETING 
ANGIOGENESIS 
 
MAY 2014 
 
WASAMON NUTAKUL, B.S., CHULALONGKORN UNIVERSITY, THAILAND 
 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Hang Xiao 
 
Cancer remains a leading cause of death worldwide. Due to angiogenesis and 
metastatic potency of cancer, chemotherapies are not adequate for metastatic tumor.  We 
investigated anti-carcinogenic effects of resveratrol in comparison to those of 
pterostilbene in colon cancer cells. We found superior activities of pterostilbene over 
resveratrol in growth inhibition as well as apoptosis induction. Higher Intracellular 
concentration of pterostilbene could contribute to its higher potency in anti-
carcinogenesis; however, both resveratrol and pterostilbene failed to inhibit colon cancer 
cell migration in vitro.  Polymethoxylatedflavones (PMFs) found exclusively in citrus 
fruits have shown inhibitory effects against cancer. We investigated their anti-angiogenic 
activities in endothelial cells as well as anti-metastatic in lung cancer cells. PMFs 
inhibited endothelial cells migration and tube formation with higher potency found in 5-
hydroxylated PMFs and their metabolites. We discovered that their inhibition is 
correlates well with their ability to interfere with cellular signaling between tumor cell 
and endothelial cells.  In lung cancer cells, PMFs inhibited cell migration and cell 
invasion. They modulate angiogenesis/metastasis related proteins. PMFs suppressed cell 
migration by down regulating upstream regulator and signaling molecule which control 
migration.  They inhibit cell invasion by disrupting upstream regulator molecules and 
inhibiting enzymes expression while inducing endogenous enzyme inhibitor.  The 
intracellular contents of 5-hydroxylated PMFs and metabolites were also investigated and 
they partially explain the different magnitude of anti-angiogenesis/metastasis among the 
PMFs compound.  
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CHAPTER 1 
INTRODUCTION 
Cancer burden is increasing worldwide.  It is now affects 24 million people 
around the world and accounted for 6 million death annually (1). Increases in aging 
populations as well as adopted cancer-causing habits result in more cancer incidents in 
developing countries. Even though fewer incidents is diagnosed, these countries has same 
level of cancer-related death as the developed countries (2).  In the United States cancer 
remains a major public health problem.  It is number one leading cause of death among 
population ages between 45-64 years old, while it ranked second to heart disease in the 
older populations (National Center for Health Statistics, CDC). Within one’s lifetime, 
individual have approximately 40% chance to be diagnose with any type of cancer (3).  
According to National Cancer Institute, 1,638,910 new cases were estimated for 2012 and 
577,190 cancer-related deaths are expected (4).  Simultaneously, cancer treatment costs 
are also arising, from $125 billion annually in 2010 to an estimated of $207 billion by 
2020 (5).  In addition to ongoing cancer treatment, the number of cancer survivals, who 
will need specify medical attention, also arising (4, 6).  To alleviate global cancer burden, 
an improvement of cancer prevention regimens are necessary. 
 Developments in the diagnosis technology have help identified early stage   
cancer cases and it has help improving the number of cancer cases, however, most 
malignancies are still diagnosed and treated at advanced stages in which therapeutic 
options are limited which result in poor survival rate.  It has been established that the 
transition from pre-invasive, dormant form of cancer to advance, metastatic phase of 
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cancer depend on angiogenesis, the formation of new blood vessels (7-10).  In 1971, 
Judah Folkman first proposed that tumor growth is angiogenesis-dependent and 
suggested tumor angiogenesis as a target for the treatment of cancer.  The first anti-
angiogenesis drug, bevacizumap was approved in 2004 and is used in combination with 
chemotherapy.  At present, several anti-angiogenic drugs are available for different type 
of advance stages tumor (11, 12).  Still, the cost and side effects of these medications 
prohibit their use for cancer prevention.  Nowadays, potent anti-angiogenic molecules 
have been identified in dietary sources (13-15).  Accumulating evidences of diet-derived 
anti-angiogenic agents present the possibility of utilizing well-designed anti-angiogenic 
diets as novel cancer prevention regimens which are relatively safe and widely available. 
According to the World Health Organization, 40% of all cancer deaths can be 
avoided by lifestyle adjustment such as lowering tobacco use and alcohol consumption, 
improving diets and increasing physical activities (16).  Diets are identified as one of the 
key components in prevention of cancer.  Epidemiological studies have shown the 
relations of higher fruits and vegetables consumption with lower risk of chronic diseases 
including cancer (17-22).  An approach of utilizing compounds for intervention in order 
to prolong or reverse the process of carcinogenesis was defined as “Chemoprevention” 
(23).  Recently, diet-derived components from fruits and vegetables have been widely 
studied for their chemopreventive abilities.  Many studies have identified phytochemicals 
as active compounds that account for anti-carcinogenic effects of fruit and vegetables and 
that they could work synergistically in the food system (24).  
Stilbene is a well-known class of phytochemical.  Resveratrol (3,5,4'-trihydroxy-
trans-stilbene), a major polyphenol found in red wine and grapes, is the most studied 
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stilbene compound.  Resveratrol process several biological activities including anti-
inflamation, anti-carcinogenic against variety of carcinoma such as colon, prostate, breast 
and pancrease.  However, the utilization of resveratrol as chemopreventive agent is 
limited by its low bioavailability (25).  Pterostilbene (trans-3,5-dimethoxy-4’-
hydroxystilbene) is the methoxylated derivatives of resveratrol that have gain increasing 
attention due to its higher stability.  Although, much less studies have been completed for 
pterosilbene, promising data are accumulating.  Pterostilbene anti-carcinogenic activities 
was observed in breast, colon  as well as other type of cancers (26). 
Polymethoxyflavones (PMFs) is a group of bioflavonoid found exclusively in 
citrus plants.  These compounds are mainly localized in the peels of citrus rather than the 
fruits.  They have demonstrate broad spectrum of biological activities including anti-
inflammatory, anti-atherogenic properties and anti-carcinogenic activities (27).  Nobiletin 
and Tangeretin are major PMFs compound found in nature and it was shown to be 
effective in inhibiting cancer cell proliferation, induce cell cycle arrest as well as inhibit 
cell invasion (28-30).  Recently, 5-hydroxylated PMFs have gain more attention since 
they have shown superior anti-carcinogenic effects than their PMFs parent compounds 
(31, 32). 
Our long-term goal is to establish diet-based regime for chemoprevention by 
targeting angiogenesis process.  To reach that goal, information on potency of diet-
derived anti-angiogenic candidates is necessary, thus the main objective of this research 
is the evaluation of Stilbenes and PMFs’ anti-carcinogenesis and anti-angiogenic 
activities on tumor microenvironment components.  Our central hypothesis is that PMFs 
process several anti-angiogenesis abilities not only in cancer cells, but also surrounding 
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cells like endothelial cells.  Our hypothesis has been cultivated on the results of 
accumulating data of Stilbene and PMFs anti-carcinogenic activities 
We aim to test our hypothesis and achieve our objectives of this research by 
following specific aims: 
1. Determine the growth inhibitory effects of stilbene compounds on human 
colon cancer cells.  The growth inhibitory effects of resveratrol and pterostilbene will be 
determine using cell viability assay.  Flow cytometry analysis will be performed to 
determine the effects of stilbene compounds on apoptosis induction.  We anticipated 
higher potency of pterostilbene over resveratrol in colon cancer cells growth inhibition. 
2. Determine anti-angiogenic effects of PMFs and their metabolites on human 
microvascular endothelial Human Microvascular Endothelial cells will be used.  The 
non-toxic concentrations of PMFs and their metabolites will be determined by cell 
viability assay.  Endothelial cells tube formation assay as well as migration assays will be 
conduct to evaluate anti-angiogenic effects of PMFs and their metabolites on endothelial 
cells.  ELISA and immunoblotting will be used to studied communication pathway 
between cancer cell and endothelial  
3. Determine anti-metastasiseffects of PMFs and their metabolites on non-small 
cell lung cancer. Cancer cell migration and Boyden chamber invasion assay will be 
performed to determine anti-metastatic activities of PMFs and its metabolites.  
Immunoblot and ELISA technique will be conduct to investigate molecular events 
involved in PMFs’ anti-metastasis activities.  We expected to observed higher anti-
angiogenic effects of PMFs metabolites than their parent compounds. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Overview of Carcinogenesis 
 The multistage model of carcinogenesis was first propose by epidemiologists 
based on an analysis of age-specific incidence of common cancers (33).  It established the 
new approach in developing cancer treatment regimen by defining three carcinogenesis 
steps; initiation, promotion and progression, which can be used as targets for therapies.  
These steps explain how normal epithelial cells progress through series of genotypic as 
well as phenotypic changes that result in an emerging of invasive cancer (34).  Initiation 
refers to the exposure of mutagens which result in an irreversible mutation of a critical 
gene.  Promotion is the development of benign tumors as a result of non-mutagenic tissue 
disruption such as wounding or inflammation.  These benign tumors contain initiated 
cells and can either regress without stimulation or recur with further promotion.  
Progression or malignant transformation is the conversion of non-invasive benign tumor 
to invasive cancer, this occurs with further tissue disruption and the exposure to certain 
genotoxic agents can increase the rate of progression (35). 
The carcinogenesis model is now well established and remains widely accepted.  
Cancer develops and progress over a long period of time as a result of the accumulation 
of genetic and/or epigenetic changes that drive the normal cells to progressively change 
into highly malignant counterparts.  In each steps of development tumor populations 
acquire characteristics that distinct them from normal cell populations.  These hallmarks 
include limitless cell proliferation, self-sufficiency in growth signals, unresponsive to 
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inhibitory signals, evading apoptosis, recruit and sustaining blood vessels (angiogenesis) 
and invade surrounding tissues (metastasis) (36).  These characteristics can be related to 
the model of multistage carcinogenesis. 
 
2.1.1 Initiation and Promotion 
Initiation is accomplished by mutation in a critical gene often in small cell 
populations.  The mutation change how initiated cells response to extracellular signal 
such as termination signals or growth signal.  This leads to cell proliferation which results 
in fixation of that mutation.  Unlike initiation, tumor promotion appears to be epigenetic 
process.  It is characterized by selection of the growth of initiated cells account for their 
clonal expansion to benign tumor (papilloma) (35).  At present, numerous genes have 
been discovered and they have specific functions and variety of roles in tumorigenesis. 
Tumor cells develop self-sufficiency in growth signals by alteration of 
extracellular growth signals, transmembrane receptor proteins, and downstream signaling 
pathways.  For example, high level of tumor growth factor α (TGF-α) and platelet-
derived growth factor was found in glioblastoma.  In stomach and brain tumors, 
epidermal growth factor receptor (EGFR/erbB) is upregulated; while human epidermal 
growth factor receptor 2 (HER2/neu) is overexpressed in breast cancers.  In term of 
downstream signaling, 25% of human cancer present with altered Ras protein, an 
upstream regulator of cell growth, that release growth signal without normal stimulations. 
Tumor cells also develop insensitivity to anti-growth signals that control the 
proper level of cell division.  The retinoblastoma protein (pRb) is one of the main 
antiproliferative pathways at the molecular level. pRb block proliferation by withheld 
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transcription factors needed for cell cycle progression. TGFβ antigrowth factor is 
function by preventing the inactivation of pRb, keeping the circuit operate.  The human 
tunors altered their TGFβ responsiveness either by down regulating its receptor or 
produced altered, dysfunctional receptor resulting in continuing cell proliferation.  
Almost all type of cancer acquired the ability to escape program cell death or apoptosis, 
the process cells used to control mutated cells.  When sensing DNA damge, the p53 
tumor suppressor proteins induce apoptosis by upregulating expression of Bax proteins 
which in turn stimulate mitochondria to release cytochrome C, starting the apoptosis 
process.  The mutation of p53 gene is found in more than 50% of human cancers, this 
result in dysfunctional p53 protein and lack of DNA damage sensor that will trigger 
apoptosis. 
Altogether, these genotypic changes can be observed by the acquired 
characteristics including growth signal autonomy, insensitivity to anti-growth signal and 
resistance to apoptosis, in the initiated cells.  As a result the expanded initiated cell 
populations increase the chance of the cell to accumulate relevant mutations in order to 
transform from benign tumor to invasive tumor.  
 
2.1.2 Tumor progression and malignant transformation 
 Progression is the transformation of a benign tumor to a malignant tumor.  This 
step is characterized by an increased independence of the tumor cells from the 
environment and the host.  It involved further genetic mutations in the expanded 
population of initiated cells.  The characteristics of cell acquire during this process 
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include the unlimited replication of cells, the ability to sustain angiogenesis and 
eventually the capability for tissue invasion and metastasis.  
The capabilities acquire during initiation and promotion allows initiated cell 
populations to grow into benign tumor, an abnormal growth of tissue that is not invasive.  
The progression to invasive cancer starts when cancers overcome the limit of their 
replication cycle.  Telomere shortening occurs naturally in every cell division cycle, it 
control how many time a certain cell can replicate.  Tumors up-regulate their telomerase 
enzyme that functions to elongate the ends of telomere, therefore maintaining its telomere 
in the dividable length and result in limitless growth of tumor mass.   
The massive cell growth is sustained by the developed capability of tumor to 
induce and sustain blood vessel formation, angiogenesis.  To progress to a larger size 
tumors activate surrounding endothelial cells from quiescent into angiogenic state.  These 
endothelial cells then initiated new vessel sprouting from previously existing blood 
vessel.  Vascular endothelial growth factor (VEGF) and fibroblast growth factor 
(FGF1/2) are some of the main factors that bind and activate endothelial cell functions, 
they found to be highly expressed in many tumors.  . 
Once blood vessels are formed and the tumor has adequate nutrient supply, the 
primary tumors grow indefinitely and start to invade surrounding tissue, in many cases 
they release pioneer cells that travel to distant site forming new colonies.  90% of cancer 
deaths are a result of metastasis.  The process of metastasis involves cells detachment 
from their surrounding and their migration.  E-cadherin proteins maintain cell-to-cell 
interaction and play a major role in cell adherent, their loss of functions found in a 
majority of epithelial cancers.  Once detached cancer cells travel throughout the body one 
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way via the tumor blood vessel.  Blood vessels are surrounded and protected by 
extracellular matrix (ECM).  To metastasize, cancer cell secrete proteolysis enzyme such 
as matrix metalloproteases (MMPs) to disrupt ECM structure opening the path for their 
migration. 
 
2.1.3 Chemoprevention 
 Cancer chemoprevention was first defined by Sporn in the 1970’s as the use of 
natural or synthetic compounds to inhibit, retard or reverse the process of carcinogenesis 
(37).  According to the process of carcinogenesis, chemopreventive agents can be roughly 
divided into three groups.  First group is the compounds that act to prevent the formation 
of carcinogens from their precursors; they may do this by modulating body’s inactivation 
and excretion process.  The second group is the “blocking agents” which function as 
inhibitors that prevent carcinogens to reach or react with their targets in the tissue. The 
third group which functions at the later step of carcinogenesis, after initiation process, is 
the “suppressing agents.”  They act by suppressing the expression of neoplastic 
characters in cells that are previously exposed with carcinogen, preventing them from 
becoming cancerous.  In many cases, chemopreventive agents have multiple targets and 
may act at different time point of carcinogenesis (38).   
 From the beginning, chemoprevention has been linked to minor nutrients as the 
first research proving the concept was done by synthetic analog of vitamin A (37).  Diet 
remains one of the major sources for identifying chemopreventive agents.  The relation of 
fruits and vegetables consumption and decreased risk of several types of cancer may 
partly result from the high content of bioactive compounds (39).  Most of these bioactive 
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compounds are synthesis naturally in plants and they possess anti-oxidative, anti-
mutagenic and anti-carcinogenic properties.  These phytochemicals have gain increasing 
attention in the field of chemoprevention research.  Not until recently, the discovery and 
usage of natural products are focusing on chemotherapeutic drug developments; 
therefore, similar to other drugs, these regimens which followed high-dose, short time 
applications have well-known side effects.  The changing trend towards chemoprevention 
is aiming to delivery functional dietary phytochemical by incorporating them into the 
diets, at low concentration with longer exposure time, in order to eliminate their possible 
side effects (40). 
 Following the simplified model of carcinogenesis (41), dietary phytochemicals 
are effective either as blocking agents and suppressing agents.  They can block and/or 
reverse the premalignant stage of carcinogenesis as well as halt or retard the development 
and transformation of cancer into malignant stage.  They express their activities via 
variety of molecular pathways that controlled key cellular processes including cell cycle 
arrest, apoptosis induction, anti-angiogenesis and inhibition of metastasis.  In addition, it 
must be noted that the activities of any chemopreventive agent is, mostly, a summary of 
many cellular and molecular events, rather than single effect (42). 
Chemoprevention can play variety of roles in interfering with tumor development 
and progression.  Thus, chemopreventive agents will not only useful for healthy 
individuals but also will be beneficial to high-risk individuals, cancer patients as well as 
post-therapy cancer patients as well.  For example, a diet rich in phytochemicals could 
lower the risk of developing cancer in healthy individual, while a purified, concentrate 
phytochemical might be used with high risk individuals.  In case of cancer patients, 
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chemopreventive compounds maybe used as adjuvant therapy in addition to other 
treatment regimens.  As for post-treatment cancer patients, a well balance diet with fruit 
and vegetables might help reduce chances of cancer relapse (40).   
 
2.2 Angioprevention by Citrus flavonoids 
2.2.1 Overview of angioprevention  
Blood vessels are composing of endothelial cells which lined and connected to 
form tubular structures that direct and maintain blood flow.  During embryogenesis, 
blood vessels originate via vasculogenesis, a primary stage of blood vessel formation, in 
which endothelial progenitor cells (EPC) form a tube-like structure, called lumen, which 
are homogeneous and give rise to the heart and primitive network of circulation system.  
These networks then develop via angiogenesis process in which previously formed vessel 
reformed and expanded their network by process of sprouting, branching and bridging.  
Angiogenesis remodel the homogeneous primary network into hierarchy of vascular tree 
composing of arteries, vein and capillaries.  In adult, new vessel can only be produced by 
angiogenesis process, and mostly vasculature remain quiescent in normal conditions (43).   
In normal tissue, the expansion of cells are control by the balance of cell division 
and cell death (apoptosis), therefore, there is no net tissue growth.  The tissue expansion 
requires angiogenesis to support the increased metabolism.  Among healthy adults, 
angiogenesis process is suppressed except for certain processes including embryonic 
development, menstrual cycle, and wound healing (44-46).  Endothelial cells are one of 
the longest-living cells in the body, only 1 in every 10,000 endothelial cells (0.01%) is in 
the cell division cycle at a given time period (47).  In adult, endothelial cells activities 
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were controlled by the balance between endogenous angiogenesis promoters and 
inhibitors (48).  This balance kept angiogenesis in place and rate of sprouting remain low, 
however; unusual stimulations, such as tumor microenvironment, can activate endothelial 
cells resulting in the growth of new blood vessels (49). 
During the expansion of tumor, they received nutrient and oxygen by simple 
diffusion from the host blood vessel.  When it get to certain size, some cells within the 
tumor, will be pushed further away exceeding the diffusion limit of oxygen from these 
blood vessels forcing the cells to go under low oxygen conditions(50) (hypoxia).  In this 
state, the tumors activate their hypoxic response, the so called “angiogenic switch”, 
resulting in an up-regulation of endothelial growth factor such as vascular endothelial 
growth factor (VEGF), that are release to initiated tumor angiogenesis (51).  When 
endothelial cells received these signals, the angiogenic balance will be disrupted and they 
will turn into pro-angiogenic state.  The endothelial cells will duplicate, migrate, and 
sprout towards the direction of angiogenic factors, in this case the tumor mass.  This 
“angiogenic switch” was studied in several animal models and was proposed to be one of 
the rate limiting steps in multistage tumorigenesis (52-54). 
It is well established that the growth of neoplastic tissue is angiogenesis 
dependent (8, 9, 55).  Without new blood vessel formation, solid tumor can only grow up 
to the size of 2-3 mm then entering dormant, yet viable state (7).  The induction of 
angiogenesis is a critical events that distinct preinvasive, dormant tumor from invasive, 
metastatic tumor.  In fact, studies have shown that the level of tumor vascularity 
positively linked to stage of cancer, the tendency of metastasis and recurrence (56).   
Antiangiogenic therapy has been approved for several types of cancer including 
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colorectal, renal, liver, lung and brain (57).  Growing body of preclinical, clinical and 
epidermiological data is indicating that angiogenesis inhibition can be used effectively in 
cancer prevention (58).                      
 
2.2.2 Molecular targets of cancer angioprevention  
Angiogenesis activity depends on the balance of several stimulators and 
inhibitors.  Angiogenesis is activate when the tumor switch from avascular stage to 
vascular stage in which angiogenic growth factors outnumber endogenous angiogenesis 
inhibitors disturbing the balance that control vascularization.  Angiogenesis require the 
degradation of extracellular matrix in combination with sprouting and migration of 
endothelial cells from preexisting capillaries.  Both pro-angiogenic (stimulator) factors 
and anti-angiogenic (inhibitor) factors can be affected by dietary flavonoid.  Herein, 
molecular markers that have been reported to be involved in citrus flavonoid 
manipulation of angiogenesis and metastasis process will be discussed. 
 
2.2.2.1 VEGF/VEGFR  
 Vascular endothelial growth factor (VEGF) is a potent angiogenic peptide which 
by to its tyrosine kinase receptor, vascular endothelial growth factor receptor (VEGFR), 
located mainly on endothelial cells.  VEGF are essential in blood vessel formation and it 
was identified as a common link of inflammation, permeability and angiogenesis.  
Among angiogenic growth factors, VEGF family and their receptor tyrosine kinases play 
a major role on tumor blood vessel formation.  once VEGF factors bind to its receptors, 
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several signal transduction messengers, such as ERK1/2 and PI3K, are activated and 
resulting in migration, proliferation, tube formation and survival of endothelial cells (59).  
 
2.2.2.2 MMPs 
 Matrix metalloproteinases (MMPs) facilitate the degradation of extracellular 
matrix (ECM).  Among these enzymes, MMP-2 and MMP-9 was identified in different 
type of tumors and they are linked to motility and invasive ability of the cells.  MMPs are 
produced in pro-enzyme form and it required activation from other protease to change 
into active MMPs.  Both MMPs are collagenase 1 and 2 which target collagen, a major 
component of ECM.  In tumor settings, ECM is a barrier between tumor mass and blood 
vessel.  Tumors degrade ECM in order to invade into the blood vessel, spread to 
secondary site and eventually forming metastases (60). 
 
2.2.2.3 uPA/uPAR 
 uPA/uPAR have become one of the marker for cancer metastasis especially in 
Ovary and  breast cancer.  The activation of pro-MMP to MMP is initiated by the 
activation of the urokinase plasminogen activator (uPA) via binding with the urokinase 
plasminogen activator receptor (uPAR).  uPA also cleaves plasminogen forming an active 
enzyme plasmin to initiated this process.  The uPAR-uPA interaction was found to be 
closely linked with enhanced motility of cancer cells (61). 
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2.2.2.4 HIF 
 Hypoxia inducible factors (HIFs) are a major transcription factor responsible for 
cell response under low oxygen conditions (Hypoxic).  The binding of hypoxia-inducible 
factor 1 (HIF-1) to the hypoxia response element (HRE) induced transcriptional 
upregulation of vascular endothelial growth factor (VEGF) which in turn  promote blood 
vessel formation .  The HIF-1 protein is a heterodimer of HIF-1α and aryl hydrocarbon 
receptor nuclear translocator (ARNT or HIF-1β).  HIF-1α and HIF-2α were identified as 
essential protein in induction of tumor metastatic phenotypes.  Under normoxic 
conditions, HIF-1α is degraded by an E3 ubiquitin ligase (von Hipple-Lindau tumor 
suppressor), however, under hypoxia, HIF-1α accumulates and transferred into nuclease 
and initiated transcription of several angiogenic proteins(62). 
 
2.2.2.5 Focal Adhesion Kinase (FAK) 
Focal adhesion kinase (FAK) is a transmembrane protein that influences cytoskeleton, 
structure of cell adhesion site to control cell motility (63).  FAK involve in integrin-
mediated signal transductions as well as other cell surface receptors.  The activated FAK 
forms a complex with Src family kinase and activate multiple downstream pathways 
through additional phosphorylation which involed in regulation of cell migration of 
various cells including cancer cells.   It has been recently establish that an increased 
expression of FAK is linked to increased invasive and metastatic potential in several 
human tumors (64). 
 
 
2.2.3 The role of citrus flavonoids
 Several dietary flavonoids demonstrate their anti
angiogenesis and metastasis
and EGCG a component from green tea.  Herein,
which can be characterized into three major groups namely 
The daily flavonoid intake in the United States for these three group combine were 
estimated to be 160-175 mg/day 
specific compounds in each group as an evident
as angiopreventive agents
Figure 2.1 Common structure of flavonoids; flavone, flavonols and flavanone 
 
2.2.3.1 Flavones 
 Flavones are a class of flavonoid
benzopyran-4-one (Fig 2.1).  
glycosides with exception of polymethoxylatedflavone in citrus fruit that appeared as 
unconjugated aglycone.  Some 
extensively studied are luteolin, apigenin, nobiletin and tangeretin
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citrus flavones such as 2’-hydroxyflavone and sinensetin  have also been identified as 
anti-angiogenic compounds.   
 
2.2.3.1.1 Nobiletin 
 Several studies have demonstrate nobiletin ability to interfere with endothelial 
cells functions including cell viability, migration and tubular structure formation (66, 67).  
The effects of flavone (20-90μM) on endothelial cells were observed in HUVEC, where 
it shown to inhibits migration and tube formation in vitro (68).  In HUVECs, nobiletin 
reduced the expression of uPA and inhibit the phosphorylation of ERK1/2, JNK and c-
Jun (66).  In addition, 5-hydroxy-3,6,7,8,3’,4’ hexamethoxyflavone, metabolites of 
nobiletin, also shown to inhibit in vitro tube formation in HUVECs (69) 
Nobiletin anti-angiogenic activity was studied by Bracke, M. who shown in vitro 
anti-invasive capacity of nobiletin (10-100μM) in MO4 mouse sarcoma cells (70).  
Rooprai, H.K. and colleges had observed superior activity of nobiletin (4 μg/ml) over 
captopril (30 μg/ml) (angiotensin-converting enzyme inhibitor) in reduction of MMP-2 
and MMP-9 activities in human brain tumor cell lines; however, the ability to inhibit cell 
migration and cell invasion are similar (71). Later, Lee, Y.-C.(72), and Kunimasa, K. (66) 
has shown anti-angiogenic effects of nobiletin on the AGS cancer cell line as well as 
HUVECs endothelial cells.  Nobiletin at 1-2 µM successfully reduced cell adhesion, 
invasion and migration of AGS cell, while higher concentration is needed (32-128µM) to 
inhibit cell migration, differentiation and tube formation in HUVECs.  Nobiletin targeted 
MMP-2 in both cell lines, it successfully decrease protein and mRNA expression.  In 
AGS cells, 2µM of nobiletin decrease the expression and activities of MMP-9, and 
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proteins involved in the regulations of the MMPs which includes PI3K, Ras, c-Raf, Rac-
1, Cdc42, and RhoA as well as inhibit the phosphorylation of FAK and Akt proteins (72).  
.  Nobiletin was shown to decrease proMMP-7 mRNA and protein level in HT29 colon 
cancer cells in a dose an time dependent manner.  In the same study, nobiletin also lower 
AP-1, an upstream transcription factor of proMMP7, DNA binding capacity (30). 
Nobiletin at the concentration of 10-100 µg was shown to inhibit vascular 
formation in the CAM assay as well as in zebrafish embryo, while the researchers does 
not observe nobiletin activity towards tumor-induced angiogenesis, they have shown its 
in vivo anti-angiogenic activity (66, 67, 73). 
 
2.2.3.1.2 Tangeretin 
Tangeretin (3,5,6,7,8,3′-hexamethoxylflavone) has been studied along the side 
with nobiletin in term of anti-angiogenic properties (70, 71).  It was shown to have anti-
invasive activity (74) with the ability to upregulate E-cadherin/catenin complex (75); 
however, later experiment revealed that tangeretin interfere with tamoxifen, a cancer 
drug, and result in adverse effect in MCF7/6-nude mice xenograft (76).  In comparison 
with nobiletin, tangeretin is less effective in down regulating MMP-2 and MMP-9 
activities in brain tumor cell lines (71).  Also, despite strong anti-proliferative activities, 
tangeretin does not show anti-metastatic activity in Lentini’s model (77).  The 
metabolites of nobiletin has not been widely studied regarding anti-angiogenesis; 
however there is some evidence shown that dihydroxylpentamethoxyflavone can inhibits 
STAT phosphorylation as well as down-regulate VEGF, and MMP-9 protein expression 
(78, 79). 
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2.2.3.1.3 Luteolin 
 Luteolin was shown in endothelial cells to be effective inhibiting cell migration 
and tubular structure formation by interfering with  enzymatic activities and protein 
expression of MMP-2 and MMP-9 and the activation of JNK/STAT3, mTOR/AKT/ERK 
and VEGFR-2 pathways (80-83).  In aortic smooth muscle cells it was shown to decrease 
PDGFR protein expression as well as PDGFR-β phosphorylation which could contribute 
to a decrease in smooth muscle cell migration and cell invasion(84).  Luteolin also 
demonstrate its inhibition on tumor cell-induced endothelial cell migration as shown in 
the co-culture model of HUVEC-PANC1 pancreatic cancer (85). 
Luteolin have been tested on several cancer cell lines including hepatoma, 
pancreatic cancer, epidermal cancer as well as lung cancer.  It was shown to inhibit 
hepatocyte growth factor (HGF)-induced cell migration and cell invasion in HepG2 
hepatoma cells. It was shown that luteolin inhibit HGF activation of c-met and it’s 
downstream signaling cascade, PI3K/ERK1/2/Akt activation (86).  It was shown to 
inhibit invasion and cell migration in prostate cancer cell lines as well as decrease the 
number of spontaneous lung metastases of PC3, prostate cancer cells.  Possible 
mechanisms include the down regulation of VEGF mRNA expression, up regulation of 
E-cadherin and inhibition of Akt phosphorylation(85, 87, 88).  The up-regulation of E-
cadherin was also found when treat A431 epidermal cancer with luteolin.  In addition 
down-regulation of MMP-9 was reported in epidermal cancer as well as glioblastoma 
cells (89, 90).  In NCI-H157 lung cancer cell, luteolin inhibit the activation of Akt and 
STAT-3 while down regulates VEGF expression (91). 
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In vivo experiments demonstrate luteolin consistency in inhibiting vascularization 
in variety of model used.  10-100μM of luteolin successfully inhibit blood vessel 
formation in CAM assay, rat aortic ring assay, rabbit cornea angiogenic assay, retinal 
neovascularization and matrigel plug model in chickenembryo(80, 81, 85, 88, 92).  The 
xenograft models reveal that luteolin decrease quantity of tumor vessel formation in 
parallel with lower tumor volumn.  This coordinates with a down regulation of MMP-2 
and MMP-9 in tumor tissue (80, 88). 
 
2.2.3.1.4 Apigenin 
 Apigenin is effective towards HUVEC endothelial cells as well as pulmonary 
smooth muscle cells.  It was shown to inhibits tubular structure formation in various in 
vitro models at a concentration lower than 50 μM (82, 93, 94), as well as inhibiting  
endothelial cell migration and invasion at a concentration lower than 20μM (82, 84, 95).  
Several pathways including PDGFR, IL6-STAT3, VEGF and MMP2 were proposed to 
be involve in apigenin effects on endothelial cells function both at mRNA and protein 
level (82, 84, 96). 
Apigenin was found to be effective toward cell adhesion, cell migration and cell 
invasion of breast, ovarian and cervical cancer (97-99).  Fang et al. has shown that 
apigenin interfere with HIF-1α and VEGF protein interaction and the stability of HIF-1α 
protein in ovarian cancer cell lines, thus result in the inhibition of angiogenic activities 
(100).  In breast cancer cells, apigenin was shown to suppress MMP-9 and uPA 
expression, the authors propose blocking of PI3K/Akt pathway as mechanism of apigenin 
(101).  In other study with breast cancer cel, VEGF was shown to be a target of apigenin 
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anti-angiogenic activity with the decrease in VEGF, VEGFR1 and VEGFR2 mRNA 
expression as well as VEGF secretion level (102).  Apigenin also affects prostate cancer 
and lung cancer cells in a similar manner, although different protein target might be 
responsible.  In prostate cancer, along with the down regulation of VEGF and HIF-1α, 
apigenin inhibit the phosphorylation of Smad2, Smad3, c-Src, ERK and Akt indicating its 
effect on the upstream protein of HIF-1α (100, 103).  In lung cancer cells, apigenin 
treatment interferes with HIF1α-promoted VEGF production (104).  Similar trend also 
found in hepatocellular carcinoma cell lines (96, 105). 
Various concentration of apigenin at was shown to successfully decrease the 
vascularization in CAM model (10-100μM), chorodial neovascularization in rats (15-30 
mg/kg), and hemoglobin content as well as tumor vascularization in matrigel plug models 
(7.5-20μM)(84, 92, 95, 104, 106). In metastatic in vivo assay with MDAMB231 breast 
cancer cells, apigenin was able to suppress lung colonization and metastasis (98, 101).  In 
in vivo melanoma model, apigenin was also shown to be effective in decrease lung 
colonization (107).  Ovarian tumor xenograft mice treated with apigenin shown a 
decrease number of metastases in the liver and bowel.  Focal adhesion kinase (FAK) was 
propose to be the target of apigenin in this study as its expression was down regulate both 
in cell culture and primary tumor tissue (99).  Lung cancer xenograft model show that 
treatments of apigenin decrease tumor growth while down regulate VEGF, HIF-1α and 
PCNA protein expression in the tumor tissue(104).   The TRAMP mice model was used 
to demonstrate efficacy of apigenin toward prostate cancer in vivo.  The feeding of 
apigenin for 20 weeks decrease well-differentiated tumor population and inhibit 
metastasis to the lung, lymph and liver.  These observations were in parallel with a 
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decrease in angiogenic markers (VEGF, MMP-2, MMP-9 and uPA) protein expression in 
the tumor tissue as well as their secretion (VEGF, uPA) from the tumor (108). 
 
2.2.3.1.5 Sinensetin 
 Sinensetin, a nobiletin derivative, has been shown to inhibit vascularization in the 
zebrafish model.  The study reported a decrease in Flt1(VEGFR1) mRNA level with the 
treatment of sinensetin and that its inhibitory effect is higher than that of nobiletin and 
hesperitin (73). 
   
2.2.3.2 Flavonols 
 Flavonols  (3-hydroxy-2-phenylchromen-4one) structure are closely related to 
flavones except that flavonols contain hydroxylation at the 3 position of their structure 
(Fig 2.1).  In general, they occur in the diet as glycoside.  Examples of diet derived 
flavonols include quercetin, kaempferol and myricetin.   
 
2.2.3.2.1 Quercetin 
 Quercetin (3,3',4',5,7-pentahydroxy-2-phenylchromen-4-one), found in many 
fruit, vegetables and plant-derived food.  In targeting angiogenesis, Quercetin and its 
derivative have been tested in in several endothelial cells model, HUVECs be the most 
common, to inhibit activities of endothelial cells which include cell growth, cell 
migration tubular structure formation and cell adhesion (93, 109-112).   Along with these 
studies, endothelial molecular markers that were effected by Quercetin includes upstream 
receptor (VEGFR2)(112, 113), downstream signaling molecules (C-Src, ERK, 
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AKT)(114), collagenase enzyme (MMP-2, MMP-9) (111) and interestingly cell adhesion 
proteins (FAK. VCAM-1, ICAM-1)(114, 115).  The concentration of Quercetin used in 
these experiments ranging from moderate to relatively high level (15-200µM). 
In in vitro models of Breast (MDAMB-231 and MCF-7), and protate cancer (PC-
3), Quercetin was shown to inhibits cell migration and cell invasion.  Its activities were 
explained by the modulation of matrix metalloprotease enzyme (MMP-3 and MMP-9) 
either by decresing their expression or lowering their enzymatic activities (113, 116-118).  
The uPA protein levels were also decreased in PC-3 prostate cancer cells treated with 
quercetin, it down regulates mRNA expression of EGF and EGFR level and inhibits the 
phosphorylation of EGFR, preventing downstream signaling.  The activity of VEGF was 
depressed with Quercetin treated Breast (MCF-7) and Lung cancer (NCI-H157), the 
down-regulation also shown in their upstream proteins, HIF-1α and pSTAT3 as well as 
their downstream protein, AKT(91, 119). It should be noted that realtively high 
concentration of quercetin (30-100µM) were used in these experiments.   
In vivo, various concentration of Quercetin (10-100μM) were used in the 
Chorioallantoic Membrane (CAM) Assay and rat aortic ring assay in which the inhibition 
of vascularization was found at low concentration of 10 μM(92, 112, 119, 120).  In 
zebrafish model, Quercetin-4’-O-β-D was shown to inhibit vascularization of both 
embryo and adult zebrafish (114).  Inhibition of lung colonization was inhibited in the 
B16-B16 melanoma-xenograft in miceand the effects were stronger than that of apigenin, 
EGCG and resveratrol (107).  The decrease of uPA activity was also observed in the 
serum of DMBA-induced mammary carcinoma animals (121).  Quercetin treatments in 
the xenograft models of lymphoma (25mg/kg), breast (1mg/kg), and mouth carcinoma 
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(25mg/kg) in rodents show lowered level of vascularization measured by CD31 marker 
and hemoglobin content compare to that of control group.  In addition, a downregulation 
of pro-angiogenic markers (HIF-1α, VEGF, MMP-2 and MMP-9) and an upregulation of 
anti-angiogenic markers (RECK and TIMP-2) is observed (112, 120, 122).  
 
2.2.3.2.2 Kaempferol 
 Kaempferol (3,4',5,7-tetrahydroxy-2-phenylchromen-4-one), found in variety of 
fruit and vegetables including broccoli, brussel sprout, grapefruit and apple.  Kaempherol 
inhibits collagen-induced tube formation in HUVECs, while most in vitro anti-angiogenic 
activities were observed in tumor models including Glioma, Lung carcinoma and ovarian 
cancer cells.  Kaemferol was shown to inhibit expression of MMP-9 protein as well as 
their enzymatic activity.  It also inhibits TPA-induced glioma cell migration and invasion 
by suppressing MMP-2 and MMP-9 enzymatic activities (89, 123).  Following kaemferol 
treatments, the upstream regulator, pSTAT3 and HIF-1α, were down regulate in lung 
(NCI-H157) and ovarian cancer (OVCAR-3, A2780/CP70), while decrease in VEGF 
pAkt and pERK) was only shown in Ovarian cancer cells (91, 124, 125).   
Limited number of in vivo studies was done using kaemferol in chicken embryo 
showing reduced vascularization in CAM and that it is comparable to quercetin. 20μM of 
kaemferol shows significant anti-angiogenic effects in matrigel plug (92, 124). 
 
2.2.3.2.3 Myricetin 
 Myricetin (3,3',4',5',5,7-hexahydroxy-2-phenylchromen-4-one), natuarally occur 
in many fruit and seeds such as walnuts, berries and herbs.  In endothelial cells, myricetin 
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inhibits tube formation and cell-cell interaction which corresponds with lower level of 
several adhesion molecules VCAM-1, ICAM-1 and E-selectin, these effects was shown 
to be comparable to quercetin(115).  In tumor cells, myricetin suppress enzymatic 
activities of MMP-2 and TPA-induced MMP-2 expression in several colon cancer cell 
lines, while its glycoside analogs does not show any effect.  In COLO 205 cells, it 
inhibits the phosphorylation of ERK protein and inhibits TPA-induced cell invasion in 
the transwell assay (126).  Similar trends were observed in human lung cancer A549 
cells, myricetin inhibits both cell migration and cell invasion in a dose and time 
dependent manner.  It was also shown to suppress MMP-2 and uPA enzymatic activities 
by inhibit the phosphorylation of ERK1/2 and prevent the translocation of NF-ᴋB 
transcription factor (127).    
 In SKH-1 hairless mice skin tumorigenesis in vivo model, myricetin shows 
several anti-angiogenic activities including diminished blood vessel formation, down-
regulation of VEGF, HIF-1α, MMPs by the regulations of PI3K/Akt as well as 
MEK/ERK pathway(128). 
 
2.2.3.3 Flavanone 
 Flavanones are a class of flavonoid found mainly in citrus fruits and are widely 
consume in western diets.  Besides proanthocyanidins, they are the most consumed 
flavonoid that account for 17% of total flavonoid intake.  In the United State, 
approximately 14.4 mg/day are consumed daily (129).  Among dietary flavanone, 
naringenin was the most studied compound, while only few studies have investigate 
hesperitin. 
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2.2.3.3.1 Naringenin 
 Naringenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one), a flavanone 
found in orange, grapefruit and tomatoes.  Naringenin inhibits the expression of HIF-1α, 
VEGF and pAkt expression in Ehrlich ascites carcinoma tumor model as well as decrease 
vascularization in the CAM assay (130).  It was shown in in vivo lung metastssis assay of 
B16-F10 melanoma to be effective in inhibiting lung metastases formation and their 
action was higher than that of hesperetin (131).  In pulmonary fibrosis mice model, 
naringenin was shown to decrease the number of lung metastasis both in passive model 
and spontaneous model, naringenin also expand the life span of mice with pulmonary 
fibrosis (132).  in vitro model of pancreatic cancer cells, panc-1, demonstrate that 
naringenin can inhibits TGF-β induced cell migration and invasion by decresing MMP-2 
and MMP-9 enzymatic activity as well as up-regulates the expression of E-cadherin(133). 
 
2.2.3.3.2 Hesperitin 
 Hesperitin (2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-
benzopyran-4-one) is aglycone form of Hesperidin (flavanone glycoside).  Hesperitin 
have been studied for its chloresterol lowering properties and potential for anti-cancer 
effects.  It was shown in diabetic rat model that treatment of 25-100 mg/kg hesperitin 
decreased VEGF and PKC-β protein expression which inhibits new capillaries formation 
in retinal and improve vascular dysfunction cause by diabetic.  This indicates the 
beneficial usage of hesperitin in improving retina vasculopathy in diabetic patients (134). 
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2.2.3.3.3 2’-Hydroxyflavanone 
2’-Hydroxyflavavone (2HF) (2-(2-hydroxyphenyl)chromen-4-one) found in 
orange and family of citrus fruit.  2HF inhibits migration of renal cancer cell (RCC) and 
by down regulation of VEGF protein and inhibits cell migration, invasion and cell-matrix 
adhesion in non-small cell lung cancer (NSCLC-A549) (135, 136). 
2’HF was tested in renal cell carcinoma (RCC) models to be effective 
angiogenesis in highly vascularized renal cancer of VHL-mutant, while does not show 
significant effects toward wild type RCC. The flavanone lowered VEGF expression in  
786-O RCC cell and decrease the expression of CD31 (angiogenic marker) and increase 
E-cadherin (anti-invasion marker) proteins in RCC-xenograft model(135).  In lung 
cancer, 2HF show inhibitory effects on cell migration, invasion and adhesion.  This could 
be partially explained by the decrease of MMP-2 and uPA enzymatic activities with an 
increase in angiogenic inhibitor; TIMP-2 and PAI proteins (136). 
 
 
2.3 Resveratrol and pterostilbene 
2.3.1 Introduction  
 Resveratrol (trans-3,5,4’-trihydroxystilbene) and pterostilbene (4’hydroxy-3,5-
dimethoxy stilbene) belong a group phytochemicals called stilbene compounds.  Stilbene 
are naturally derived polyphenols produced by plants in response to environmental stress 
such as fungal or microbial infection.  Resveratrol are found in cranberries, peanut, 
grapes and red wine, while pterostilbene can be found in blueberries.  Resveratrol and 
pterostilbene share the same structure backbone of stilbene core with the different of two 
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methoxylated position on pterostilbene structure.  Both compounds have shown several 
biological activities toward inflammation cancer and cardiovascular disease (137, 138). 
 
2.3.2 Bioactivities of resveratrol and pterostilbene 
 Resveratrol have been show to processes antioxidant, anti-aging, anti-
inflammation, vascular support as well as anti-carcinogenic activities.  Due to the concept 
of French paradox, resveratrol was investigate for protective effects toward 
cardiovascular disease, it was found that resveratrol inhibits the expression of C-reactive 
protein (CRP), a clinical marker for cardiovascular risk.  It also increase the activity of 
endothelial nitric oxide synthase (eNOS) enzyme which convert L-arginine into nitric 
oxide, promoting vascular health (139, 140).  Anti-carcinogenesis of resveratrol is 
extensively studied in breast cancer.  Resveratrol was shown to induce apoptosis in MCF-
7 and MDA-MB-435 breast cancer cell lines by interfering with estrogen  receptor-
dependent PI3K pathway which regulates calpain inhibiting NF-ᴋB translocation and 
promoting apoptosis (141).   
 Pterostilbene possesses potent anti-oxidant, anti-inflammation as well as anti-
carcinogenic activities.  Pterostilbene effectively induced apoptosis in several type of 
cancers such as colon, lung and breast cancer.  In colon cancer models, pterostilbene was 
shown to inhibit in vivo colon tumorigenesis in rats.  It was shown to down-regulate Myc, 
cyclin D, β-catenin as well as inhibit phosphorylation of NF-ᴋB preventing its 
translocation, thus inhibit downstream signaling of tumorigenesis (142). 
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2.3.3 Anti-angiogenesis and anti-metastasis activities of stilbene compounds 
 Resveratrol was shown to inhibits bovine aorta endothelial (BAE) cell migration 
and in vitro tube formation as well as cell migration and vascular endothelial growth 
factor (VEGF) productions in other endothelial cell lines (143, 144).  In lung cancer 
model, resveratrol suppressed metastasis by inhibiting epithelial-to-mesenchymal 
transition (EMT) via down-regulation of E-cadherin.  It also inhibit cell adhesion as well 
as cell migration ability of A549 lung cancer cells (145).  Resveratrol was shown to 
decrease microvessel density in MDA-MB-231 xenograft model partially by down-
regulating VEGF secretion (146). 
 The metastatic growth in the liver in mice inject with B16-F10 melanoma cells 
pretreated with pterostilbene was lower than that of control group (147).  Pterostilbene 
suppress TPA-induced invasion, migration and metastasis of HepG2 hepatoma cells via 
down regulations of MMP-9 mRNA level as well as MMP-9, VEGF and EGFR protein 
expression (148). 
 
2.4 Polymethoxyflavones and their metabolites 
2.4.1 Introduction  
 As a great source of vitamin C, citrus fruit and juice have always been perceived 
as beneficial for human health and well incorporate into human diets.  As of 2012-2013 
seasons, citrus production in the United States was estimated to be 1.42 million boxes, 
equivalent to 9.37 million tons of oranges (USDA-National Agricultural Statistic Service 
report, 2012).  34% of these productions are used in juice production, yielding 44% of 
peels as byproducts (149).  Originally, citrus peels were used as a source of industrial 
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pectin, essential oil and antioxidant in food and cosmetic products (150-153).  A 
successful used of citrus essential oil as anti-oxidant leads to the identification of many 
functional compounds such as phenolic acids and flavonoids.  The peels were shown to 
have higher content of flavonoids than the seeds (154). 
In addition to their high content of vitamins and minerals, citrus also contain 
many bioflavonoids.  Citrus flavonoids can be catagorized as flavones, flavanones, 
flavonols and flavans.  Generally, citrus flavonoids are found in glycosides form (bound 
to sugar moieties), except for polymethoxylated flavones which they can be found as free 
aglycones (155).  Polymethoxyflavones is a term for flavones bearing two or more 
methoxy groups on their basic benzo-ɣ-pyrone skeleton with a carbonyl group at the C4 
position (Fig 2.2). 
Polymethoxyflavones (PMFs) present in the minor amount in the crude extract of 
citrus flavonoids (156).  They exist mainly in the citrus genus, particularly in the peel of 
sweet orange (Citrus sinensis) and mandarin oranges (Citrus reticulata).  More than 20 
PMFs were isolated and identified from different tissue of citrus plants in which the type 
and contents of PMFs varied depending on citrus species.  In sweet orange peel eight 
hydroxylated PMFs, six PMFs, one polymethoxyflavone were identified (157).  Beside 
their anti-oxidant activities, PMFs also demonstrate anti-atherogenic, anti-inflammatory 
as well as anti-carcinogenic activities (27, 158, 159). 
 
2.4.2 Biotransformation of polymethoxyflavones 
 Although most dietary flavonoids are present in glycoside form, PMFs are 
exception, they naturally present as free aglycones.  In the gastrointerstinal tract, a 
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fraction of flavonoids is degraded by gut microflora, while the other portion is absorbed 
through the small intestine.  After absorption, flavonoids are distributed via body fluids 
and tissue either unchanged and/or in conjugated forms.   
 
 
Figure 2.2  Common structure of citrus polymethoxyflavones (E. Tripoli, et al. 2007) 
 
 The metabolic pathways of PMFs compounds are relatively similar to each other 
in which 3’ and 4’ position in the B-ring are the primary sites of biotransformation (27).  
Their metabolic paths are different from other general flavonoids which may be due to 
their lipophilic nature (160).  Several studies have shown that PMFs are subjected to 
hydroxylation and demethylation reactions.  In an experiment with rat liver microsome, 
Nielsen found that CYP1A isozymes are the major enzymes involved in flavonoid 
hydroxylation, while other cytochrome P450 isozymes are involved in demethylation 
(161). 
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As the major PMFs found in different type of citrus peels (162), nobiletin 
(5,6,7,8,3’,4’-hexamethoxyflavone) and tangeretin (5,6,7,8,4’-pentamethoxyflavone) 
have been studied for their metabolic paths which could partially represent PMFs 
biotransformation.  The treatment of nobiletin with a rat liver microsomal enzyme S9 
mixture, which mimic liver metabolism, result in the formation of 3’hydroxylnobiletin 
(M1) , 4’hydroxynobiletin (M2) and 3’4’dihydroxynobiletin (M3) (163, 164).  In animal, 
after feeding rats with nobiletin, their urine contain detectable amount of 
4’hydroxylnobiletin as the main metabolites (165).  Murakami also detect 
3’hydroxylnobiletin and two dihydroxylnobiletin in urine while only 3’hydroxylnobiletin 
was detected in serum (160).  Another study where mice were feed with nobiletin also 
revealed 4’-hydroxylnobiletin (M2) as the major metabolites in the urine, while 
3’hydroxylnobiletin (M1) was found at a lower level (166).   
Tangeretin metabolisms are somewhat similar to that of nobiletin.  Rat liver 
microsomal enzyme treatments reveal three metabolites of tangeretin which are 4’-
hydroxyl-5,6,7,8-tetramethoxyflavones, 3’-hydroxyl-5,6,7,8-tetramethoxyflavones and 
3’4’-dihydroxyl-6,7,8-trimetoxyflavones(161).  the in vivo biotransformation study on 
tangeretin shown that 4’ hydroxyl-5,6,7,8-tetramethoxyflavones was identified as major 
metabolites in both urine and feces sample, followed by 3’,4’-dihydroxyl-5,6,7,8-
tetramethoxylflavone in the urine and 4’,6,7-trihydroxy-5,8-dimethoxyflavone in the 
feces (167). 
 Several biotransformation studies have revealed the metabolites of PMFs to be 
hydroxylated counterparts of their parent compounds and that these metabolites have 
been shown to have superior effects as anti-inflammation as well as anti-carcinogenesis.  
Our laboratory has performed a biotransfomation studies and was able to identify several 
metabolites after feeding the mouse with nobiletin (Fig 3.7).  
Figure 2.3 Chemical structure of polymethoxyflavones (PMFs) and their metabolites 
found in urine and feces of mice after feeding with nobiletin.  The name in parenthesis 
are chemical name follows IUP
differents from their parent compound and acronym on the top left of each structure ar
the name that will be refer to
 
2.4.3 Bioactivities of polymethoxyflavones and metabolites
 Nobiletin and its hydroxylated metabolites were shown to have different 
magnitude in inhibiting inflammation in RAW264.7 macrophage.  
does not show significant reduction of inflammation, its metabolite; 3’
(M1), 4’-hydroxynobiletin
nitrite production as well as down
(168).  In TPA-stimulate mouse skin mo
(M3) by topical application resulted in reduct
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authors explain that M3 decrease the upstream proteins activities of NF-ᴋB/IᴋB, and 
MAPKs/PI3K/Akt pathways.  These molecular events were correlated with decrease skin 
thickness and lowered white blood cells in mouse skin treated with M3, indicating 
decrease in skin inflammation (169).  
 PMFs anti-carcinogenic activities vary depending up on specific number and 
position of methoxy groups on their structure.  Recently, it was found that the 
hydroxylation at position 5 of PMF structure may enhance their activities.  In Hela cells, 
both PMFs and hydroxylated PMFs shown growth inhibition; however, only 
hydroxylated PMFs demonstrated strong pro-apoptotic activity (159).  Similar trend was 
found with colon cancer cells.  HCT116 and HT29 cells treated with 5-hydroxylated 
PMFs gone into G1/G0 and G2/M cell cycle arrested and apoptosis, while the cells 
treated with permethoxylated PMF show no significant changes.  Their mechanism was 
explain by an increase in negative regulator of cell cycle progression  (p21, 
phosphorylated Rb), a decrease in cell cycle activator (K-ras), an increase in apoptotic 
markers (cleaved caspase3 and cleaved PARP) as well as decrease in inflammation 
marker (iNOS) (31, 32).   
 
2.4.4 Anti-angiogenesis and anti-metastasis activities of polymethoxyflavones 
Nobiletin anti-angiogenic activity was first studied by Bracke, M. who shown in 
vitro anti-invasive capacity of nobiletin (10-100μM) in MO4 mouse sarcoma cells (70).  
Rooprai, H.K. and colleges had observed superior activity of nobiletin (4 μg/ml) over 
captopril (30 μg/ml) (angiotensin-converting enzyme inhibitor) in reduction of MMP-2 
and MMP-9 activities in human brain tumor cell lines; however, the ability to inhibit cell 
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migration and cell invasion are similar (71). The effects of flavone (20-90μM) on 
endothelial cells were observed in HUVEC, where it shown to inhibits migration and tube 
formation in vitro (68). Later, Lee, Y.-C.(72), and Kunimasa, K. (66) has shown anti-
angiogenic effects of nobiletin on the AGS cancer cell line as well as HUVECs 
endothelial cells.  Nobiletin at 1-2 µM successfully reduced cell adhesion, invasion and 
migration of AGS cell, while higher concentration is needed (32-128µM) to inhibit cell 
migration, differentiation and tube formation in HUVECs.  Nobiletin targeted MMP-2 in 
both cell lines, it successfully decrease protein and mRNA expression.  In AGS cells, 
2µM of nobiletin decrease the expression and activities of MMP-9, and proteins involved 
in the regulations of the MMPs which includes PI3K, Ras, c-Raf, Rac-1, Cdc42, and 
RhoA as well as inhibit the phosphorylation of FAK and Akt proteins (72).  In HUVECs, 
nobiletin also reduced the expression of uPA and inhibit the phosphorylation of ERK1/2, 
JNK and c-Jun (66).  Nobiletin was shown to decrease proMMP-7 mRNA and protein 
level in HT29 colon cancer cells in a dose an time dependent manner.  In the same study, 
nobiletin also lower AP-1, an upstream transcription factor of proMMP7, DNA binding 
capacity (30).  In addition, 5-hydroxy-3,6,7,8,3’,4’ hexamethoxyflavone, metabolites of 
nobiletin, also shown to inhibit in vitro tube formation in HUVECs (69).  Nobiletin at the 
concentration of 10-100 µg was shown to inhibit vascular formation in the CAM assay as 
well as in zebrafish embryo, while the researchers does not observe nobiletin activity 
towards tumor-induced angiogenesis, they have shown its in vivo anti-angiogenic activity 
(66, 67, 73). 
Due to the similarity of the structure and dietary source, tangeretin (3,5,6,7,8,3′-
hexamethoxylflavone) has been studied along the side with nobiletin in term of anti-
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angiogenic properties (70, 71).  It was shown to have anti-invasive activity (74) with the 
ability to upregulate E-cadherin/catenin complex (75); however, later experiment 
revealed that tangeretin interfere with tamoxifen, a cancer drug, and result in adverse 
effect in MCF7/6-nude mice xenograft (76).  In comparison with nobiletin, tangeretin is 
less effective in down regulating MMP-2 and MMP-9 activities in brain tumor cell lines 
(71).  Also, despite strong anti-proliferative activities, tangeretin does not show anti-
metastatic activity in Lentini’s model (77).  The metabolites of nobiletin has not been 
widely studied regarding anti-angiogenesis; however there is some evidence shown that 
dihydroxylpentamethoxyflavone can inhibits STAT phosphorylation as well as down-
regulate VEGF, and MMP-9 protein expression (78, 79). 
 
2.4.5 Bioavailability of polymethoxyflavones 
 Bioavailability is an overall effect of absorption, distribution, metabolism and 
excretion.  It is quantify by the portion of a compound that present in the blood 
circulation system and reach the tissue after digested and absorbed in gastrointestinal 
tract (GI).  In chemoprevention, intracellular accumulation and metabolisms of 
chemopreventive agents are crucial factors dictating their efficacy.  In practice, 
bioavailability of certain compounds is quantified by plasma concentration. 
 In case of polymethoxyflavones, the information on their bioavailability is still 
lacking.  In vitro experiment with initiated Caco-2 cells reveal that 48.1% of nobiletin 
permeate through differentiated Caco-2 cells, which mimic epithelial components in the 
small intestine, after 4 hour of incubation, while luteolin, a polyhydroxyflavones, does 
not (163).  In a followed up experiment, Murakami et al studied the absorbtion and 
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metabolism of nobiletin in male SD rats over 24 h period.  They found that nobiletin 
accumulate in the mucous membrane of the small intestine and mucaris of the stomach 
for up to 4 hours, while the smaller amount were detect in the large intestine.  In addition, 
they also found the accumulation of nobiletin in the liver and kidney and 1 and 4 hour in 
which higher anmount was found in kidnet at 4h than that at 1 h.  The higher localization 
of nobiletin at the stomach suggest possible key absorbtion site.  Molecular 
hydrophobicity was believed to influence the pattern of organ localization.(160) 
 In pharmacokinetic study of male Sprague Dawley rats, 50 mg/kg of nobiletin or 
tangeretin were administered to the rats and serum concentration of both compounds 
were monitored.  The maximum plasma concentration of nobiletin and tangeretin are 9.03 
μg/mL and 4.5 μg/mL accordingly.  The level of nobiletin remains higher than 2 μg/mL, 
while tangeretin level was 0.65 μg/mL.  Even after 24h after treatment, nobeletin was 
present at a higher concentration than tangeretin indicating higher absorption of nobiletin 
(170). 
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CHAPTER 3 
INHIBITORY EFFECTS OF RESVERATROL AND PTEROSTILBENE ON 
HUMAN COLON CANCER CELLS: A SIDE BY SIDE COMPARISON 
 
3.1 Introduction 
Colon cancer is one of the deadliest cancers in the United States, and was ranked 
the third cause of cancer death (171).  Moreover, an increase in colon cancer incidence in 
adult under 50 years old has been reported (172).  Cancer chemoprevention has been 
considered as a promising strategy to controlling cancer death, especially in colon cancer, 
because the generally slow progression of colorectal adenomatous polyps of colon cancer 
allows better opportunities for chemoprevention regimen. Results from epidemiological 
studies have linked fruit and vegetable consumptions with reduced risk of colon cancer, 
and multiple phytochemicals have been identified as potential cancer-fighting agents 
from commonly consumed fruits and vegetables. 
Stilbene is a class of natural polyphenolic compounds that has been studied for 
their health-promoting effects including the anti-carcinogenic activities (173).  The core 
chemical strucuture of stilbene compounds is 1,2-diphenylethylene (Figure 1).  Trans-
resveratrol (3,4’,5-trihydroxy-trans-stilbene; REV) (Fig 1A) are the most widely studied 
stilbene found in small fruit such as grape, berries, peanuts, and some medicinal plants 
(174).  Resveratrol has been considered as a good anti-carcinogenic agent because of its 
low toxicity and capability of modulating multiple molecular pathways involved in 
cancer progression (175).  These pathways play important roles in cell cycle progression, 
anti-apoptosis, angiogenesis, and tumor invasion. Studies have demonstrated that 
resveratrol was anti-proliferative, proapoptotic, and anti
culture models (176-178)
tumor progression in multiple organ sites such as breast, prostate, lung and 
gastrointestinal tract (179
cancer chemoprevention is that resveratrol has low systemic bioavailability 
which may lower its efficacy in humans. Consequently, more efforts have been exerted to 
develop resveratrol derivatives with better bioavailability profiles.
Figure 3.1. Chemical structure of resveratrol and pterostilbene 
 
3.2 Materials and Methods
3.2.1 Treatment and cell cultures
Resveratrol and pterostilbene were obtained from Quality Phytochemical LLC. 
(New Jersey, USA).  The 100 mM stock was prepared 
dimethyl sulfoxide (DMSO). Human colon cancer cells HCT116, HT29, and Caco
were obtained from American type cell collection (ATCC, Manassas, VA), and were 
maintain in McCoy’s 5A or RPMI media (ATCC, Manassas,VA) supplemente
heat inactivated FBS (Mediatech, Herndon, VA), 100 U/mL of penicillin, and 0.1mg/mL 
streptomycin (Sigma-Aldrich) at 37
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confluent and media were change every other day.  All cells used were within 3 to 30 
passages.  DMSO was used as the vehicle to deliver resveratrol and pterostilbene, and the 
final concentration of DMSO in all culture media was 0.1% 
 
3.2.2 Cell viability assay 
HCT116 (1500 cells/well), HT29 (2000 cells/well) or Caco-2 (3000 cells/well) 
cells were seeded in 96-well plates.  After 24 h, media were replaced with 200 µL media 
containing serial concentrations of resveratrol or pterostilbene.  After suitable treatment 
period, cells were subject to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay.  The treatment media was replaced by 100 µL fresh media 
containing 0.5 mg/mL of MTT (Sigma-Aldrich).  After 2 h incubation at 37˚C, MTT-
containing media were removed and the reduced formazan dye was solubilized by 
addition of 100 µL DMSO to each well.  After gently mixing, the absorbance was 
monitored at 570 nm using a micro-plate reader (Elx800TM absorbance microplate 
reader, BioTek Instrument, Inc., Vermont). 
 
3.2.3 Colony formation assay 
HCT116 (750 cell/well), HT29 (750 cell/well) and Caco-2 (750 cell/well) cells 
were seeded in 6-well tissue culture plate.  After 24 hour incubation for adhesion, the 
media were replaced with treatment media containing serial concentrations of resveratrol 
or pterostilbene.  The treatment media were refreshed every other day. After 10 days 
incubation, the colonies were stained with crystal violet solution (0.2% crystal violet in 
2% ethanol) for 10 min, and followed by a gentle rinse with warm tap water to remove 
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any free dye.  One mL of  SDS-solution (0.5% SDS in 50%EtOH) was added to each 
well to solublize the bound dye, and the absorbance of the solution was measured at 570 
nm using a micro-plate reader (Elx800TM absorbance microplate reader, BioTek 
Instrument, Inc., Vermont) to quantify colonies formed (182).  
 
3.2.4 Detection of Apoptosis 
Apoptosis induction was quantified by Annexin V/PI double staining followed by flow 
cytometry.  Annexin V/PI double staining was performed using an apoptosis detection kit 
(Biovision, Mountain view, CA) following the manufacturer’s instruction.  In short, Cells 
were gently detached by brief trypsinization (any floating cells were also collected), and 
then washed with ice cold PBS. After another wash with binding buffer, cells were 
suspended in 300 µL binding buffer containing Annexin V and propidium iodide, and 
incubated for 5 min at room temperature. Early apoptotic cells were identified as Annexin 
V positive/PI negative cells, while late apoptotic/necrotic cells were identified as 
Annexin V positive/PI positive cells using a BD LSR II cell analyzer. 
 
3.2.5 Immunoblotting 
Human colon cancer cells were seeded in 10-cm cell culture dishes.  After 24 h, cells 
were treated with serial concentrations of resveratrol or pterostilbene.  Cells were 
incubated for another 24 or 48 h, washed with ice-cold PBS, incubated on ice for 10 mins 
in lysis buffer (Cell signaling, Beverly, MA, USA) supplemented with cocktails of 
protease inhibitor (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) 
(50mM), Aprotinin (30mM),  Besstain Leupeptin (1mM))(1:100); phosphatase inhibitor 
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1( Imidazole sodium fluoride, Sodium molybdate Sodium orthovanadate, Sodium 
pyrophosphate tartrate) (1:100), and phosphatase inhibitor 2 (Sodium fluoride, Sodium 
orthovanadate, Sodium pyrophosphate, b-glycerophosphate)(1:100) (Boston Bioproduct, 
Ashland, MA, USA).  Cell suspension were subject to sonication (5 s, three times), 
followed by incubation for another 20min on ice.  The cells were then centrifuged at 
15325 RCF for 20 min at 4˚C, and supernatants were collected.  Protein content were 
quantified using BCATM protein assay kit (Thermo Scientific, Rockford, IL), and 20-
50µg of protein was resolved by SDS-PAGE and transferred to nitrocellulose membrane.  
After blocking, proteins of interest were probed using different antibodies at 
manufacturer’s recommended concentrations (1:500-1:1000), and then visualized using 
enhanced chemiluminescence (Boston Bioproducts, Ashland, MA).  Antibodies for beta-
actin, cleaved PARP, and cleaved caspase-3 were from Cell Signaling Technology, Inc. 
(Beverly, MA). 
 
3.2.6 Wound healing assay  
 HCT116 (10,000 cells/well) were seeded in 24 well-plate and allow to grow to 
confluence.  The cell monolayers were scraped with 200μL tips to created “gap” area 
then the media was replaced with treatment media containing serial concentrations of 
resveratrol or pterostilbene.  The pictures of the gap area were taken at 0, 24 and 48h.  
The wound healing (%) were calculated from gap width at endpoint of the experiment 
(48h) as relative to gap width at origin (0h). 
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3.2.7 Determination of intracellular levels of resveratrol and pterostilbene 
Colon cancer cells (2×105 cells) were suspended in 1 mL culture media containing 
different concentrations of resveratrol or pterostilbene in glass culture tube, and then 
incubated at 37°C with 5% CO2 and 95% air for 0.5, 1, or 2 hours.  The cell suspensions 
were centrifuged in a bench-top centrifuge at 491 RCF for 2 minutes at 4°C.  Supernatant 
was removed and cells were suspended in 1ml of ice-cold PBS and then centrifuged at 
491 RCF for 1 minute at 4°C.  After supernatant was removed, 1ml of buffer (pH 7.5, 
10mM-Tris-Hcl, 1mM EDTA, 1mM MgCl2) was added to suspend the cells. The cell 
suspension was kept on ice for 5 minutes before cells were sonicated with a probe 
sonicator (5 sec, 3 times). After another centrifugation (15325 RCF  for 25 minutes at 
4°C), the supernatant was collected as cytosol fraction. Appropriate amount of MeOH 
was added to cytosol fraction to make the final MeOH concentration 40%. Equal volume 
of ethyl acetate was then used to extract resveratrol and pterostilbene (twice). The pooled 
ethyl acetate fractions were evaporated to dryness, reconstituted in 50% MeOH, then 
analyzed using HPLC method reported previously (183).  
 
3.3 Results 
3.3.1 Pterostilbene is more potent than resveratrol in inhibiting colon cancer cell 
growth and colony formation 
 We compared the inhibitory effects of resveratrol and pterostilbene on three colon 
cancer cell lines using cell viability (MTT) assay. The results showed that resveratrol and 
pterostilbene caused dose-dependent inhibition of the cell viability of all three cancer 
cells (Fig. 3.2). Among these cells, HCT116 cells were the most sensitive to resveratrol 
and pterostilbene treatments, while Caco
cells were more sensitive to pterosti
treatments. Pterostilbene showed IC
resveratrol was 4.3-fold higher (about 65 
pterostilbene were about 12 and 75 
25 µM and > 100 µM, respectively.
Figure 3.2. Growth inhibitory effect of resveratrol (REV) and pterostilbene (PTS) on 
HCT116, HT29, and Caco
HT29 (B), and Caco-2 (C) were seeded in 96
with serial concentrations of resveratrol or pterostilbene.  After 48 hr of treatments, cell 
viability was measured by MTT assay
as mean ± standard deviation (SD). All results for resveratrol and pterostilbene at the 
same concentrations were significantly different from each other except the noted * (p < 
0.01). 
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50 of about 15 µM in HT29 cells, while IC
µM). In HCT116 and Caco-2 cells, IC
µM, respectively, and IC50 of resveratrol were about 
 
-2 human colon cancer cells.  Colon cancer cells HCT116 (A), 
-well plates.  After 24 h, cells were treated 
 as described in the Methods. Data were expressed 
50 of 
50 of 
 
Next, we determined th
colony formation of colon cancer cells. After 10 days of incubation, all three cancer cells 
produced substantial colonies in vehicle treated controls (Figure 3). The sensitivity of 
three cancer cells to the pterostilbene and resveratrol treatments was in the order of
Caco2 > HT29 > HCT116. 
Figure 3.3.  Effects of resveratrol (REV) and pterostilbene (PTS) on colony formation of 
HT29 (A), HCT116 (B), and Caco
seeded in 6-well plates and then treated with resveratrol or pterostilbene at concentrations 
indicated in the figure. The media containing resveratrol, pterostilbene, or vehicle control 
were changed every other day.  After 10 days of incub
with crystal violet and quantified as described in methods. The amount of colonies 
formed by control cells was set as 100%. Data were expressed as mean ± standard 
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deviation (SD). In the bar figures, the different notation indicates statistical difference 
based ANOVA analysis (p < 0.01). 
 
Pterostilbene showed stronger inhibitory effects on all three cancer cells in comparison 
with resveratrol. For example, pterostilbene at 10 µM suppressed the colony formation of 
HT29 and HCT116 cells by 85% and 40%, respectively, while resveratrol at the same 
concentration decreased the colony formation by only 32% and 9%, respectively. In 
Caco-2 cells, pterostilbene and resveratrol at 5 µM caused 79% and 54% inhibition on the 
colony formation, respectively. 
 
3.3.2 Pterostilbene shows stronger inducing effects on apoptosis in colon cancer cells 
than resveratrol 
To determine the mechanism by which pterostilbene and resveratrol inhibit the 
growth of cancer cells, we determined the extent to which treatments of resveratrol or 
pterostilbene induced apoptosis in colon cancer cells. After 48 hr treatments, cancer cells 
were subject to double-staining by Annexin V and PI to quantify early and late apoptosis 
by flow-cytometry (Fig. 3.4A-C). Representative dot plots from double-staining assay 
were showed in Fig. 3.4A.  In HT29 cells, resveratrol at 25 µM did not significantly 
induced apoptosis, while pterostilbene at same concentration was able to increase the 
level of apoptotic cell population to 14.7% (2.7-fold of the control). This level was even 
higher than that produced by resveratrol at 75 µM (Fig. 3.4A and B). In HCT116 cells, 
pterostilbene showed similar level of inducing effects on total apoptotic cell population 
than resveratrol at the same concentration.   We further determined the effects of 
pterostilbene and resveratrol on the levels of two key pro-apoptotic proteins, i.e., cleaved 
caspase 3 and cleaved Poly (ADP
analysis demonstrated that pterostilbene had 
levels of cleaved caspase-
 
Figure 3.4. Effects of resveratrol (REV) and pterostilbene (PTS) on apoptosis of colon 
cancer cells. Cells were treated with serial concentration of resveratrol and pterostilbene 
for 48 h, then subject to Annexin V/PI co
dot plots of HT-29 after treatments with resveratrol or pterostilbene. Quantification
early and late apoptosis after different treatments was shown in (B) HT29 and (C) 
HCT116 cells.  (D) The immunoblot of cleaved caspase
and HCT116 cells after treatments with resveratrol and pterostilbene.  The numbers 
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underneath the blots represent band intensities (normalized to the loading controls, means 
of three independent experiments) measured by Image J software. The standard 
deviations (all within ±15% of the means) were not shown. The experiments were 
repeated for three times. β-Actin were used as equal loading controls. 
 
 For example, in HT29 cells, pterostilbene at 50 µM increased the level of cleaved 
caspase 3 to an extent that was about 4-fold of that produced by resveratrol at 50 µM, and 
similar to that produced by resveratrol at 75 µM (Fig. 3.4D left panel). Moreover, 
pterostilbene at 50 µM is about 20-time and 3-time stronger than resveratrol at 50 µM and 
75 µM, respectively, in inducing the cleavage of PARP protein. In HCT116 cells, 
pterostilbene at 30 µM was about 2 folds more potent that resveratrol at same 
concentration in inducing the cleavage of caspase-3 and PARP proteins. (Fig. 3.4D right 
panel).  
 
3.3.3 Resveratrol and pterostilbene does not show significant cell migration 
inhibition in HCT116 colon cancer cells 
 Our results show positive anti-carcinogenic activites of resveratrol as well as 
pterostilbene, by growth inhibition as well as apoptosis induction.  We then ask whether 
these tow compound would be effective as anti-angiogenic agent or not, thus we perform 
wound healing assay to investigate their ability in inhibiting colon cancer cell migration.  
The treatment of resveratrol and pterostilbene does not show significant inhibition of the 
cell migration (Fig 3.5) as at the endpoint of the experiment, the confluency of cell in the 
treatment groups are almost the same as that of control group.  Resveratrol at 100μM 
show some inhibition of approximately 75%, while Pterostilbene at 100 μM was too toxic 
for the cells, thus the confluency % cannot be quantified. 
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Figure 3.5 Resveratrol and Pterostilbene does not show significant inhibition of colon 
cancer cell migration.  HCT116 cells were seeded into 24-well plates. After 24h, the cells 
were wounded and serial concentration of resveratrol or pterostilbene were added into 
each well.  Images were taken at 0, 24, and 48 h.  data represent mean ±SD. 
 
3.3.4 Pterostilbene shows superior intracellular concentration to resveratrol in colon 
cancer cells. 
Bioavailability is an important factor dictating the bioactivity of food components in 
human. Using HPLC method, we determined the intracellular levels (bioavailable 
fraction to the cancer cell) of pterostilbene and resveratrol in colon cancer cells after 
incubation with the two compounds at 10 µM for 0.5, 1.0, or 2.0 hrs. In Caco-2 cells, the 
intracellular levels of pterostilbene were much higher than those of resveratrol at all three  
time points, and the levels of pterostilbene and resveratrol remained relatively constant 
from 0.5-2 hr (Fig. 3.6A). Similar results were observed in HCT116 cells (Fig. 3.6C). In 
HT29 cells, the level of pterostilbene at 0.5 hr was the highest followed by a drastic drop 
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(5-6-folds lower) at 1.0 and 2.0 hr (Fig. 3.6B). Nevertheless, the levels of pterostilbene 
were much higher than those of resveratrol at all three time points.  
As shown in figure 3.6D, AUC (area under the curve) was calculated for 
resveratrol and pterostilbene from 0 to 120min based on the results from figure 3.6A-C.  
The results demonstrated that the accumulated amount of intracellular pterostilbene was 
much higher than that of resveratrol in all three colon cancer cells. Specifically, AUC of 
pterostilbene were 2.6, 4.1, and 2.2-fold higher than those of resveratrol in Caco-2, HT29, 
and HCT116 cells, respectively. 
 
3.4 Discussion 
As a stilbene compound, resveratrol has been widely studied because of its 
various health promoting potentials, while in recent years, pterostilbene has attracted 
increasing attention in terms of its unique biochemical properties. Resveratrol and 
pterostilbene share an identical stilbene core structure, but differ in functional group, i.e., 
resveratrol possesses a 3,5-dihydroxy motif in the A ring, while pterostilbene has a 3,5-
dimethoxy motif instead.  Previous reports have suggested that chemical structure 
modification such as methoxylation could enhance bioactivities of stilbene compounds 
(184, 185). Herein, we compared the effects of resveratrol and pterostilbene in multiple 
human colon cancer cells.  
We determined the inhibitory effects of pterostilbene and resveratrol on the 
growth of three human colon cancer cells, i.e., HCT116, HT29, and Caco-2 cells. These 
cells have different genetic aberrations and gained different growth aggressiveness. For 
example, HCT116 cells contain wild type APC, mutant β-catenin, and mutant K-RAS; 
Figure 3.6 Intracellular levels of pterostilbene and resveratrol in colon cancer cells. 
Cellular uptake of resveratrol and pterostilbene in the cytosol of Caco
and HCT-116(C) human colon cancer cell lines. Colon cancer cells were incubated with 
10µM of resveratrol or pterostilbene for 0.5, 1.0, or 2.0 hr. The intracellular 
concentrations of resveratrol and pterostilbene were measure by HPLC method in Caco
(A), HT29 (B), and HCT116 (C) cells. Data were expressed as mean ± standard deviation 
(SD). The experiments were repeated for three times. All results for resveratrol and 
pterostilbene at the same concentrations were significantly different from each other (*: p 
< 0.01). 
 
HT29 cells are APC
protein; whereas Caco-2 cells contain mutant APC,
RAS. Consequently, they showed different sensitivities to the treatments of pterostilbene 
and resveratrol. However, the results from cell viability assay demonstrated that a
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types of cancer cells were more sensitive to pterostilbene treatments than resveratrol 
treatments. These findings are consistent with a previous report showing that 
pterostilbene had stronger inhibitory effects on [3H] incorporation into the DNA of cancer 
cells (186). We further demonstrated that both resveratrol and pterostilbene significantly 
reduced the capacity of all three types of human colon cancer cells to form colonies. 
These results indicated that both compounds were able to inhibit anchorage-dependent 
growth that is the early process of cancer transformation (187).  More importantly, our 
results showed that pterostilbene had stronger inhibitory effects on the colony formation 
in comparison to resveratrol in all three cancer cells tested. Overall, our results 
convincingly demonstrated that pterostilbene is a superior inhibitor to resveratrol on the 
proliferation and expansion of all three types of human colon cancer cells in culture. 
In order to establish the mechanism by which resveratrol and pterostilbene inhibit 
colon cancer cell growth, we studied the effects of the two compounds on cellular 
apoptosis. As a programmed cell death process, apoptosis is a mechanism the organism 
uses to eliminate unwanted or damaged cells.  During cancer development, adequate 
mutations can allow the mutated cells to evade apoptosis and become cancerous; thus, the 
induction of apoptosis in pre-cancerous and cancer cells is an effective strategy for cancer 
treatment and prevention (188).  In the annexin V/PI co-staining assay, we observed that 
both resveratrol and pterostilbene were able to increase apoptotic cell population. 
Moreover, pterostilbene showed stronger capacity in inducing cellular apoptosis than 
resveratrol in both HT29 and HCT116 cells. This was evidenced by increased annexin V 
positive cell population and cleavage of key apoptosis-related proteins, i.e., caspase-3 and 
PARP. Caspase-3 is the key player in both death receptor-mediated and mitochondria-
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mediated apoptosis.  The cleavage of caspase-3 activates the protein, and results in 
proteolytic cleavage of downstream proteins, such as PARP.  PARP plays an important 
role in DNA repair; thus, the inactivation (cleavage) of PARP by caspase-3 results in the 
accumulation of unrepaired DNA and eventually leads to cell death (189). Pterostilbene 
was also found to be more effective than resveratrol in inducing apoptosis in other types 
of cancer cells such as Fas-ligand resistant lymphoma cells (HUT78B1 and HUT78B3) 
and the multi-drug-resistant leukemia cells (HL60-R and K562-ADR) (190, 191).  
Bioavailability is an important factor that can dictate the efficacy of bioactive dietary 
components. Only bioavailable fractions of dietary compounds can be accessible to the 
target cells and/or tissues, and subsequently be bioactive to these cells and/or tissues.  We 
measured the intracellular levels of pterostilbene and resveratrol in colon cancer cells 
after incubation with the two agents separately. These intracellular levels are indicators of 
cellular uptake efficacy of pterostilbene and resveratrol by cancer cells.  Our results 
demonstrated that, in all three colon cancer cells, the intracellular levels of pterostilbene 
were much higher than those of resveratrol after incubation with pterostilbene or 
resveratrol at the same concentration. This suggests that cancer cells can uptake 
pterostilbene more efficiently than resveratrol, and pterostilbene is more bioavailable to 
these cells than resveratrol. Recently, the bioavailability of pterostilbene and resveratrol 
were compared in rats after oral gavage at the same doses, and the results showed that 
plasma levels of pterostilbene were markedly greater than the plasma levels of resveratrol 
(192). In our study, the higher intracellular levels of pterostilbene than resveratrol found 
in colon cancer cells may be associated with higher lipophilicity of pterostilbene due to 
substitution of two hydroxyl groups by methoxyl groups in comparison with resveratrol 
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(193, 194). Increased lipophilicity may promote binding of pterostilbene to the plasma 
membrane, which in turn may increase the uptake of pterostilbene into the cytosol of the 
cells. It is also possible that colon cancer cells have different preference in uptaking 
pterostilbene and resveratrol. The exact mechanism by which the methoxylation may 
modulate the bioavailability of pterostilbene is an attractive topic for future investigation. 
As the consequence of better cellular uptake, the higher intracellular levels of 
pterostilbene can cause more potent inhibitory effects on colon cancer cells in 
comparison with resveratrol. Another possible reason, for the superior inhibitory effects 
of pterostilbene to resveratrol on colon cancer cells, is that pterostilbene may have higher 
binding affinity to same target signaling proteins than resveratrol, and/or pterostilbene 
may have different target binding proteins from resveratrol due to the difference in their 
chemical structures. The interaction between pterostilbene and these target signaling 
proteins may cause downstream events that eventually lead to apoptosis and growth 
inhibition. Identification of these target proteins is a challenging yet promising area that 
warrants more future research. 
Taken together, our study reveals the superior anti-carcinogenic effects of 
pterostilbene to resveratrol in three human colon cancer cells in culture.  These effects 
include inhibition of cell viability, inhibition of colony formation capacity, and induction 
of apoptosis. Our results also demonstrated that the higher cellular uptake of pterostilbene 
by cancer cells in comparison to resveratrol may contribute to the superior anti-
carcinogenic effects of pterostilbene to resveratrol.  This study supports the notion that 
pterostilbene is a promising cancer-fighting dietary component due to its stronger anti-
carcinogenic effects and better bioavailability in comparison to resveratrol. 
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CHAPTER 4 
ANTI-ANGIOGENIC EFFECTS OF POLYMETHOXYFLAVONES AND THEIR 
METABOLITES ON ENDOTHELIAL CELL FUNCTIONS 
 
4.1 Introduction  
 It is recently well established that tumor microenvironment is inseparable 
component of carcinogenesis.  It involves in tumor growth, angiogenesis, epithelial to 
mesenchymal transition (EMT), invasion, migration and metastasis.  The tumor 
microenvironment contributes of endothelial cells, macrophages, cancer-associated 
fibroblasts and extra-cellular matrix(195).  Endothelial cells assemble to form the linings 
of the blood vessels walls; pericytes and vascular smooth muscle cells combine to create 
the outer layers of capillary, allowing the endothelial tubes to withstand the force of 
blood pressure; and cancer cells which activates new blood vessel formation.  All of these 
components demonstrate the complexity of tumor angiogenesis, thus the search for 
potential anti-angiogenesis agents must take these intracellular and intercellular 
communication into account. 
Among all of the components of tumor microenvironment, endothelial cells is one 
of the most crucial  target in tumor angiogenesis prevention and/or treatments due to their 
major roles in blood vessel formation (196).  Under normal conditions, endothelial cells 
which lining the blood vessel do not divide and their proliferation, migration, 
differentiation and survival are highly regulated in order to keep blood vessel formation 
at its normal rate except for during menstruation or tissue damage where new blood 
vessel is needed.  With the present of angiogenic stumuli, the inert endothelial cells will 
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re-enter the cell cycle, migrate and form capillary sprout that are functionally adapted to 
their tissue environment (197).  However, within tumor environment this well controlled 
system is disrupted by irregular growth signals from the tumors and resulting in abnormal 
neovascularization (49, 197, 198).   
In consideration of developing treatment for cancer therapy, endothelial cells are 
genetically more stable than cancer cells as they are one of the longest-living cells in the 
body with very low turnover rate (47); thus, they will accumulate less mutations that may 
cause drug-resistant (195).  This character of endothelial cell made them a promising 
candidate for chemotherapy and/or prevention.  In addition, targeting the tumor blood 
vessel instead of the specific organ where the tumor maybe presented is considered more 
effective because the treatment can reach the tumor blood vessel prior to a specific organ.  
This substantiates the idea of using tumor endothelium and/or blood vessel system as a 
target for cancer treatments.   
Some considerations that should be pointed out is that when it comes to targeting the 
tumor blood vessel, side effects can be a very hazardous because blood vessels are 
spreading throughout the body and if anti-angiogenic compound acts on the normal 
functioning blood vessel instead of tumor blood vessel it could disrupt the blood system 
and cause severe symptom.  Thus, it is important to for the anti-angiogenesis compound 
will target only the proliferating blood vessel or it will be used at the concentration that 
will result in no or lowest side effect possible.  The development of targeting treatments 
is ongoing, while the usage of anti-angiogenic compound as adjuvant therapy alongside 
with traditional chemotherapy is the main procedure that have been followed at present 
(199).   
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The inhibitory effects of citrus flavonoids towards endothelial cells have been 
shown in several in vitro models of endothelial cells.  The most studied citrus flavonoid 
in endothelial model is quercetin followed by apigenin and luteolin.  They were shown to 
be effective in inhibiting endothelial cells proliferation, migration and tubular structure 
formation all of which are essential for blood vessel formation (82-84, 110, 111, 115).  In 
comparison, Nobileitn, the polymethoxyflavone in citrus peel are less well known for 
their inhibition towards endothelial cells.  It was shown to inhibit endothelial cells 
functions and modulating angiogenic protein expression (66).   
We are interested in the inhibitory effects on endothelial cell function of 
polymethoxyflavones compounds specifically nobiletin and 5-hydroxy nobiletin.  Our 
pharmacokinetic studied in rodents successfully identified the major metabolites of both 
PMFs.  The metabolites found contain different number and position of hydroxylated 
group on the original nobiletin structure as described in earlier chapter.  Along with their 
metabolites we investigated anti-angiogenic activity of Nobiletin and 5-hydroxy 
nobiletin.  Using cell culture model of Human Microvascular Endothelial cells, we 
studied PMFs and their metabolites effects on endothelial cell functions that related to 
tumor angiogenesis.  We first investigate the endothelial cellular response to PMFs in 
would healing assay and tube formation assay.  In addition, we also investigate PMFs 
activities on key signaling pathway between tumor cells and endothelial cells: the HIF-
1α/VEGF/VEGFR pathway by immunoblotting and ELISA.  
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4.2 Material and methods 
4.2.1 Cell Culture and treatments 
Human micro vascular endothelial cells (HMVECs) were kindly provided by professor 
Rong Shao of pioneer valley life science institute (PVLSI)(Springfield, MA), and were 
culture in EBM-2 (Lonza, )media supplement with 10% heat inactivated Fetal Bovine 
Serum (FBS), 100 Units/ml Pennicellin, and 0.1 mg/ml streptomycin, 0.01% 
Hydrocortisol, and  0.01% Epidemial growth factor (EGF).  The cells were maintain at 
80-90% confluence at 37˚C, 5% CO2, and 95% air.    Matrigel basement membrane 
matrix was purchased from BD Bioscience (Bedford, MA).  Monoclonal antibody against 
vascular endothelial growth factor receptor 2 (VEGFR2/Flk1) were purchased from 
Santacruz Biotechnology.   
 
4.2.2 Cell viability assay 
HMVECs (25,000-100,000 cells/well) were seeded onto 96-well plate and after 24 hours 
the cells were treated with serial concentration of polymethoxyflavones and their 
metabolites.  After incubation for 24, 48, and 72 hours, the media will be replaced with 
assay media containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT)  at 2 mg/ml (Sigma-Aldrich).  After 0.5-2 hours of incubation at 37°C, the MTT 
solution will be replaced with 100μL/well of DMSO to solubilized remaining reduced 
formazan dye.  After gentle mixing, the absorbance will be determined at 570mm with a 
microtitre plate reader (Elx800TM, BioTek Instrument, VT, USA). 
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4.2.3 Wound healing assay 
HMVECs (5×104 cells) were seeded onto 24-well plate and were allowed to grow to 
confluence.  The cells were washed with PBS and the cell monolayer was scraped with 
200µl tip to create the gap. The treatment media containing serial concentration of PMF 
and metabolites was added to each well and pictures were taken at 0, 12, 24, 36 and 48h.  
The wound healing percentages were calculated from gap width in each timepoint 
compare to 0 h and the data were shown in confluency (%) of the gap area.  At the 
endpoint of the experiment, wound  healing (%) capacity were calculate. 
 
4.2.4 Tube formation assay 
50uL Matrigel was added in each well of 96-well plate, and let solidified for 30 minutes 
at 37 °C according to manufacturer instructions (BD biosciences).  HMVEC (100,000 
cells) were suspended in 1 mL complete media in glass tubes with or without serial 
concentration of PMFs and metabolites.  100 μL of cell suspension were then seeded into 
matrigel-coated wells and allow for incubation at 37 °C, with 95% humidity, 5% CO2 for 
12 hours.  After incubation, the cells were fixed with 4% fixative formaldehyde and the 
pictures were taken.  Numbers of tube formed were counted and percentages for tube 
formation inhibition were calculated as followed:  
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4.2.5 Enzyme-linked immune sorbent assay (ELISA) 
H1299 (25×104) cells were seeded into 6-well plates.  After 24 h, the media was replaced 
with treatment media containing 5HN, M4, M5, M6 and incubate for 24 hours.  The 
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media for each well was collected and centrifuged at 2,147 × g, 4°C for 10 minutes.  the 
supernatant was collected and stored at -80°C until ELISA assay are performed.  ELISA 
was done according to manufacturer protocol (R&D system, Minneapolis, MN).  The 
assay was done in duplicate and repeat at least twice. 
 
4.2.5 Immunoblotting 
Cells were seeded into 15 cm petri dish.  After 24 hours, the cell were treated with serial 
concentration of PMF and metabolites, and incubate for 72 hours.  Floating cells were 
collected; cells were washed with ice-cold PBS and then incubate for 10 min on ice with 
lysis buffer supplement with phosphatases and protein inhibitors.  Total protein 
concentrations were quantified by BCA™ protein assay kit, 50-150µg of protein was 
resolved by 8-12% SDS-PAGE and transfer to nitrocellulose membrane.  After blocking 
with blocking buffer, protein of interest were probed using specific primary antibodies at 
manufacturer’s recommended concentration,  then probe with florescence secondary 
antibodies specific to each primary antibody.  The protein bands were visualized using 
Odyssey fluorescence reader (Li-cor biosciences, Lincoln, NE, USA) 
 
 
4.3 Results 
4.3.1 PMFs and their metabolites show low toxicity towards endothelial cells 
 To investigate the ability of PMFs and their metabolites in the aspect of 
angioprevention compounds, non-toxic concentrations must be defined.  We tested 
HMVECs cellular toxicity of Nobiletin (NBT), M1, M2, M3, 5HN, M4, M5 and M6 
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using cell viability (MTT) assay.  As shown in Fig 4.1 the treatments of HMVECs with 
Nobiletin, M1, M2 and M3 does not show sign of toxicity even at higher concentration of 
50μM, while the treatments of 5HN, M4, M5 and M6 show stronger growth inhibition in 
which their IC50 are ranging from 24 to 39 μM.  Comparing growth inhibition of 
polymethoxyflavone (NBT), monohydroxy PMF (5HM) and di-hydroxy PMF (M4) (Fig 
4.1C) we observed a superior inhibition of hydroxylated metabolite over that of its 
permethoxylated counterpart.  M4 is the strongest compound in growth inhibition with 
the lowest IC50, therefore it will be used at a lower concentration in other experiments.   
Figure 4.1 Cell viability assay of polymethoxyflavones (PMFs) and their metabolites on 
HMVECs cell.  Endothelial cells HMVEC were seed in 96
treated with serial concentrations of PMFs and their metabolites.  After 72h, cell viability was 
measured by MTT assays as described in the methods section.  Growth inhibition of H1299 by 
(A) NBT, M1, M2, M3 and (B) 5HN
compare to 5HN and M4. Data were expressed as mean ± standard deviation (SD).
 
4.3.2 PMFs and metabolites inhibit endothelial cell migration at different magnitude
Endothelial cell migration is 
endothelial cells received the growth signals and proliferate.  When they have enough 
newly divided cells, they 
blood vessel and migrate to form ne
on endothelial cell migration, wound healing assay are performed.  
scratched to create a gap, the cells were treated with PMFs and their metabolites and the 
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-well plates.  After 24 h, cells were 
, M4, M5, M5. (C) represent growth inhibition of NBT 
one of the beginning steps in angiogenesis 
will detach from their original location in the formerly exist 
w blood vessels.  To investigate the ability of PMFs 
Monolayer of cell w
 
 
 
after the 
as 
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images were taken in a time-dependent manner.  Cell migration inhibitions were express 
in wound healing percentage.   
The result demonstrate that nobiletin, 5HN, and their metabolites have the ability 
to inhibits endothelial cell migration as we can see the migration rate of treated cells are 
lowered with the applications of these compounds (Fig 4.2A).  No significant changes in 
migration rate were observed over time.  The treatment of HMVECs with M2, M1, NBT 
and M3 at 50 µM inhibits 50%, 40%, 30% and 10% of cell migration accordingly.  M2 
was the strongest compound among nobiletin metabolites.  However, 5-hydroxylated 
PMF were shown to have stronger cell migration inhibition in which the treatment with 
10 µM of M6, M5 and 5HN inhibited 50%, 40% and 30% of cell migration, while 3µM  
M4 inhibited more than 90% of cell migration.  The data indicates M4 as the compound 
with strongest migration inhibition among PMFs (Fig 4.2) which correlates well with its 
activity in growth inhibition observed earlier. 
Since we are interested in the context of how hydroxylation of the PMF 
compounds modulated theirs activities, we compare nobiletin, 5HN and M4 at the same 
concentration (10μM) for their cell migration inhibition (Fig.4.3).  Consistently, M4 
show almost fifteen times stronger inhibition than that of nobiletin and about three times 
stronger than that of 5HN.  The migration inhibition capacity were 90%, 35% and 6% for 
M4, 5HN and NBT respectively (Fig 4.3B).  NBT rarely inhibits cell migration as the 
confluency almost reaches completion.  5HN show significant inhibition compare to 
control and NBT, but much lowers than M4 
Figure 4.2 Endothelial cell migration inhibition
compounds. The cell monolayer were “wounded” by scraping and the picture were taken at 6, 18, 
24 h. (A) Time point progression of cell migration followed the treatment of NBT, M1, M2, M3, 
5HN, M4, M5, M6.  Each data po
treatment (6, 18, 24 hours).  (B) Endpoint pictures at 24 h of wound healing assay at 40x 
magnification. 
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 by PMF metabolites compare to parent 
int represents an average cell migration at different time after 
 
Figure 4.3 Endothelial cell migration inhibition by Nobiletin, 5HN, and M4. (A)
migration inhibition followed the treatment these compounds at 10
24 h of wound healing assay at 40x magnification.  The cell monolayer were “wounded” by 
scraping and the picture were taken at 3, 6, 9, 12, 24 h.  the 
cell mololayer at the end of experiments
 
4.3.3 PMFs and metabolites inhibit endothelial cell tube formation.
After endothelial cell successfully migrate to the location of new sprouting, they 
create new vessel by diffe
that will eventually allow blood flow.
mean of in vitro matrigel tube formation assay.  
significant inhibition while the treatment of NBT, M2 and M3 at 25
20%, and 25% of tube formation and the inhibition 
Consistent with  previous experiment, 5HN, M4, M5 and M6 required lower 
concentrations.  At 10 μM 5HN, M
formation while the treatment of M4 at the concentration as low as 1.5
prevent the formation of tube formation (Fig 
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µM. (B)Endpoint pictures at 
number represent % confluency of the 
 
 
rentiate and constructing themselves into a tubular structure 
  We studied the ability to inhibit tube formation by 
The treatment of M1 does not show 
μM inhibits 30%, 
is does-dependent (Fig 
5 and M6 inhibits 54%, 90% and 77% of tube 
μM appeared to 
4.4B).  The inhibition of tube formation can 
 Degree of cell 
4.4A).  
be seen by smaller tubular structure, 
cells.  With the treatments of high potency compounds (Fig 4.4B; M2 and M4)
endothelial cell fail to change their structure
Figure 4.4 Tube formation inhibition by PMFs and thei
suspension was prepared at desired cell density.  Treatments were added into 1 mL cell 
suspension and the cells were seeded onto a matrigel
cells were fixed and the pictures were t
area indicating tube formation inhibition capacity for each treatments in realtion to control. (A) 
NBT, M1, M2 and M3 were used at 25 and 50 
20 µM.  (C) Represent endpoint pictures of each treatments.  The experiment was done in 
duplicate and repeated at least three times.  The data were present as mean ± SD.
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disconnection between differentiated endothelial 
 into tube-like structure.  
r metabolites.  The HMVECs cell 
-coated 96-well.  After 12 h incubation, the 
aken.  The graphs represent a relative percent of closed 
µM.  (B) 5HN, M4, M5 and M6 were used at 1.5
, 
 
-
 
 To investigate in more detail in the effects of M4, 0.5 
tube formation assay.  We found that 0.75 and 1
20% and 40% of tube formation (Fig 
tube formed with M4 treatment have thinner structure and incomplete 
4.5B).  In relative comparison at 1 
while 5HN, M5, and M6 show 
Figure 4.5 Endothelial cells tube formation inhibition by the treatment of M4. (A) Degree of tube 
formation inhibition express in relative percentage of closed area to control. (B) Endpoint pictures 
of endothelial cells tube formation with treatment of 0.5, 0.75, 1
in complete media with or without M4, then plate onto pre
The cell were fixed, then pictures were taken by SPOT program
 
4.3.4 PMFs modulate endothelial cells function partly by interruption of key 
angiogenesis signaling pathway: HIF
 The results in cell migration 
of PMFs on endothelial cells
further into the HIF-1α/VEGF/VEGFR2
at the beginning of tumor 
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μM-1μM were tested in 
μM of M4 can inhibit approximately 
4.5A).  Compare to the tube in the control group, 
network (Fig 
μM, M4 demonstrate 37% inhibition of tube formation 
5%, 9%, and 8% inhibition of tube formation.
µM The cells were resuspended 
-coated well and incubate for 12 hours. 
 
-1α/VEGF/VEGFR2 
and tube formation show effective inhibitory effects 
, in particular 5HN and its metabolites.  We then investigate 
 signaling pathway that activates endothelial cells 
angiogenesis process.  Using the immunoblotting technique
  
 
 we 
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first investigate the effects of 5HN, M4, M5, and M6 on upstream protein in tumor cells, 
hypoxia inducible factor (HIF-1α).  The applications of 5HN (10μM), M4(1μM), 
M5(10μM) and M6 (10μM) decrease protein level of HIF-1α by 14%, 49%, 24%, and 
56% respectively (Fig 4.5A).  It should be noted that M4 show effective HIF-1α 
reduction at a relatively low level of 1μM.  The decrease in transcription factor correlates 
with the reduction in VEGF growth factor secretion detected by ELISA after the 
treatment of tumor cells with 5HN (10μM), M4(1μM), M5(10μM) and M6 (10μM) (Fig 
4.5B).  Similar trend to HIF-1α is observed in which at 10μM, M6 inhibition (55%) on 
VEGF secretion is higher than that of 5HN (40%) and M5 (39%), while M4 is 
significantly stronger in which 1μM of M4 decrease VEGF secretion by 49%. 
From the data presented in the tumor cell model, we have shown that the 
applications of 5HN and its metabolite modulate protein expression and secretion pattern 
within HIF-1α/VEGF axis, we then investigate how these compounds will affects the 
expression of receptor protein located on the endothelial cells membrane, VEGFR-2.  
VEGFR-2 is the main receptor in the angiogenesis process as it binds with VEGF from 
the tumor cells and start endothelial cells activation process.  Western blot analysis 
demonstrates that endothelial cells treated with 5HN and metabolites show lower 
expression level of VEGFR-2 protein (Fig 4.6C).  At 10 μM, 5HN, M5, and M6 decrease 
VEGFR2 expression level by 35%, 31%, and 33%, while 1μM of M4 show highest 
inhibition despite the lower concentration used at 40% inhibition of receptor protein 
expression.  It should be noted that from the viability assay M4 at this concentration does 
not show toxicity to HMVECs cells. 
 
Figure 4.6 5HN and metabolites 
communication.  (A) The immunoblot of Hypoxia inducible factor 1 alpha (HIF
cells after treatments with 5HN
protein secretion level of H1299 cells after treatments with 
µM) and M6 (10 µM)as detected by ELIS
immunoblot of vascular endothelial growth factor receptor 2 (VEGF
48 h treatment with 5HN (10 
separated by 12% SDA-PAGE, blot with primary and 
according to manufacturer instruction.  Protein bands wer
reader using iStudio program.  The experiment were done at lease three times
 
 
4.4 Discussion 
 Polymethoxylatedflavones, have
inhibition.  This study is the first study to explore
metabolites in the context of
shown to be active in both in endothelial cells as well as in cancer cells
metabolites have not been study in 
69 
 
interfere with HIF-1α/VEGF/VEGFR2 axis of tumor
 (10 µM), M4 (1 µM), M5 (10 µM) and M6 (10 µ
5HN (10 µM), M4 (1 
A following manufacturer instructions.  (C)  The 
R-2) in HMVECs cells after 
µM), M4 (1 µM), M5 (10 µM) and M6 (10 µM).  The protein were 
fluorescence secondary antibodies 
e detected by Odyssey Fluorescence 
 
 been shown to be effective towards cancer 
 Nobiletin, 5-hydroxynobiletin and their 
 anti-angiogenic agents. Nobiletin and tangeretin have been 
; h
of the aspect of anti-angiogenic activities.  Herein, we 
 
-endothelial 
-1α) in H1299 
M).  (B)  VEGF 
µM), M5 (10 
owever, their 
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investigate the activities of nobiletin and 5-hydroxynobiletin metabolites compare to their 
parents compounds, utilizing in vitro endothelial cells models. 
 Non-toxic concentrations were used to rule out any inhibition activities due to cell 
death.  All of the compounds tested were able to inhibit endothelial cells migration and 
most were able to inhibit endothelial cells tube formation, with M4 being the most 
effective.  Permethoxylated PMFs were less effective and required almost double the 
concentration to observed inhibition activities.  The endothelial migration inhibition 
capacity were M4>M6>M5>5HN in 5-hydroxylated PMFs and M2>M1>NBT>M3 in 
PMFs.  Among 5HN and its metabolites, the number and position of hydroxylation seems 
to play role in their inhibition activities.  In most cases 5HN show weaker inhibition than 
the metabolites, while M4 which contain hydroxylation at 5 and 3’ position seem to be 
the strongest compound compare to other metabolites.  The comparison of the same 
concentration of NBT, 5HN and M4 demonstrate the effect of higher number of 
hydroxylation in which di-hydroxylated M4 show strongest inhibition (90%) followed by 
mono-hydroxylated 5HN (35%) and permethoxylated NBT (6%).  Interestingly, not only 
the number of hydroxylation is necessary for higher inhibition, but the position of 
hydroxylation also affects the activities in PMFs compounds.  Considering M6, which 
contain hydroxylation at 5, 3’ and 4’ positions does show higher inhibition than M5 in 
endothelial cells, but it did not show higher inhibition than that of M4.  This might be a 
result of how hydroxylation affects the polarity of the compound and eventually how the 
compound interacts with its protein target within the cells.  Tube formation is a crucial 
endothelial function during the process of angiogenesis.  Herein, we showed that the 
application of nobiletin, 5-hydroxynobiletin and their metabolite can inhibit endothelial 
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tube formation at different magnitude.  Similar to the trend observed in migration 
inhibition, among nobiletin and its metabolites M2 show strongest inhibition and M4 is 
the strongest among 5HN metabolites.  Both compounds inhibit endothelial tube 
formation completely at the concentration tested.  M4 is very effective at tube formation 
inhibition in which as low as 0.75-1μM show significant inhibition, while its IC50 is 
approximately 20μM.  This mean that M4 can be uses as anti-angiogenic agent at a very 
low level that will not cause toxicity, this low concentration will allow a combination of 
treatment to be applied together to improve the outcome.     From our data, hydroxylation 
of PMF compound increases theirs inhibition activity 
From the cellular studies which demonstrate effectiveness of PMF in endothelial 
functions, we studied how PMFs might modulate cellular signaling from the tumor cells 
to endothelial cells.  We focused on the major angiogenic pathway of HIF-
1α/VEGF/VEGFR signaling.  In the tumor cells, transcription factor HIF-1 is activated 
when there is not enough oxygen, they triggered transcription of VEGF protein.  VEGF 
will then be released from tumor cells and travel to bind with its receptor, VEGFR-2, 
presented on the endothelial cells membrane to initiate tumor angiogenesis in order to 
access to adequate oxygen and nutrient from new blood vessel.   VEGFR-2 is a main 
target for angiopreventive drug such as pazoranib (Votrient), a tyrosine kinase inhibitors.  
We demonstrate here for the first time that the treatment of 5HN and its metabolites 
interfere with this process.  5HN (10μM), M4(1μM), M5(10μM) and M6 (10μM) 
successfully decrease the expression of HIF-1α and its downstream product VEGF in 
tumor cell as well as decrease the expression level of VEGFR-2 receptor in the 
endothelial cells.  The data is consistent throughout all of the markers of interest in which 
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M4 remain the strongest compound at a relatively low concentration of 1 µM.  M4 was 
shown to inhibit upstream protein regulators, such as STAT-3 and IᴋBα (78, 79), in 
cancer cells; however, we are the first to show their protein modulation in endothelial 
cells.  It is crucial to point out that our experiments demonstrate a superior activities of 
M4 than that of other PMFs compound tested as a much lower concentration is needed to 
established effective cellular and molecular responses.  Ten-time higher concentration is 
needed for M5 and M6 to show comparable activities, while 5HN at ten-time higher 
concentration remain weaker inhibitors for angiogenesis. 
 Since 5HN and its metabolites show stronger inhibition than its parent compound, 
the number of hydroxyl substitution as well as their positions play role in PMFs 
effectiveness in inhibits cell migration, tube formation and modulation of protein markers 
manipulation.  This is consistent with previous studies that demonstrate hydroxylation at 
the 5 position of the A-ring to be necessity in their inhibition abilities (31, 32).  In 
addition, the hydroxylation in the B-ring of polymethoxylated flavones structure as found 
in M4, M5, and M6 also linked to higher activities (200).  The higher inhibition capacity 
of M4 could also indicate the importance of hydroxylation at 3’ position of PMF 
structure; however, hydroxylation in both positions seem necessary as a compound with 
only one position of these hydroxylation (M1 and 5HN) are not as effective as M4.  In 
contrast, some studies have shown a decrease in anti-bacterial activity when 
hydroxylation is found at 3’ position on the B-ring of PMF structures (200, 201).  This 
may indicate that different functional groups are required for different inhibition 
activities of the PMF compounds. 
73 
 
Altogether, this data reveal that PMFs and metabolites, especially 5HN 
metabolites are good candidates for anti-angiogenic agents.  They are effective in 
inhibiting endothelial cells function as well as interrupting the communication between 
tumor and endothelial cells.  The position and number of hydroxylation was shown to be 
essential in PMFs activities, thus the structure manipulation may be useful in enhancing 
their bioactivities as well as their bioavailability. 
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CHAPTER 5 
ANTI-CARCINOGENIC EFFECTS OF POLYMETHOXYFLAVONES AND 
THEIR METABOLITES TARGET HUMAN NON-SMALL CELL LUNG 
CANCER METASTASIS PROCESS 
 
5.1 Introduction 
 Lung cancer is a major cause of cancer-related death worldwide; it is the number 
one cause of cancer death among men and women in the United States (4).  Non-small 
cell lung (NSCLC) responsible for more than 80% of lung cancer cases which only 15% 
of five-year survival rate.  Advance stage NSCLC patients die within 18-month of 
diagnosis in which more than 70% of these death is a result of metastatic spread (202).  
The high mortality rate of this type of cancer could be account for difficulty in early 
diagnostic as well as metastatic nature of the diseases.  In many cases, the metastases to 
several organs are already develop at the time of diagnosis (203).  Therefore, the 
development of adjuvant therapy targeting lung cancer metastasis is essential in 
improving the lives of lung cancer patient as well as lessening the chance of high risk 
individual in developing metastatic lung cancers.  At present, combination of 
antiangiogenic therapy with cytotoxic drug have been shown to enhance antitumor 
activity and result in better outcome, thus the development of new agents with 
antiangiogenic/antimetastatic activity is at its essential stage (204). 
 Polymethoylatedflavones (PMFs) is a group of citrus bioflavonoids found highly 
concentrated in the peel of citrus fruit.  They have been shown to be highly effective in 
anti-carcinogenesis process in different type of cancer including colon, breast and 
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leukemia cell lines (29, 69, 159).  In lung cancer, PMFs and hydroxylated PMFs was 
shown to inhibit the growth of non-small cell lung cancers by intervene with cell cycle 
progression and induce apoptosis, in which 5-hydroxylated forms are more effective than 
their parent compounds (31).  Several citrus flavonoids such as quercetin, luteolin, 
apigenin, and 2’hydroxyflavanone have been shown to be effective in inhibition the 
process of metastasis both in vitro and in vivo.  They can successfully inhibit cancer cell 
migration, invasion and adhesion by targeting crucial protein targets which regulate such 
processes (91, 136).  PMFs and its 5’hydroxylated counterpart has been shown to be 
effective as anti-angiogenesis agent in colon cancer cell models (32, 69).  Herein, we 
explored PMFs anti-metastasis activities by using non-small cell lung cancer models to 
gain more understanding of PMFs efficacy as anti-carcinogenic agents.   
Cancer cell migration and invasion is an important character for cancer 
metastasis.  After tumor gain their own blood vessel via tumor-induced angiogenesis, 
unlimited supply of nutrients will allow them to grow large enough to shed their cells 
from the primary tumor mass into the tumor blood vessels.  These cells then migrate via 
the blood stream and invade to secondary tissue/organ.  Thus in anti-metastasis regime, 
we focus on inhibiting cell migration and cell invasion abilities of the tumor cells.  With 
the nature of natural compounds that usually targeting more than one protein targets we 
also explored major pathways involving in cellular migrations and cell invasions.  From 
the initiation of cell migration, to initiating invasion, and degradation of extra cellular 
matrix, we studied how each PMF and its metabolites affects protein markers in each step 
of metastasis.  
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5.2 Materials and Methods 
5.2.1 Cell Culture and treatments 
H1299 human lung carcinoma were obtain from ATCC and were culture in RPMI media 
supplement with 10% heat inactivated Fetal Bovine Serum (FBS), 100 Units/ml 
Pennicellin, and 0.1 mg/ml streptomycin. The cells were maintained at 37˚C, 5% CO2, 
and 95% air.  Polymethoxyflavones and metabolites are dissolved in dimethylsulfoxide 
(DMSO) to desired concentration in which the concentration of DMSO does not exceed 
0.1%.  All of the primary antibodies used are from Cellsignal (Danvers, MA) or 
Santacruz biotechnology (Santacruz, CA).  Florescence secondary antibodies are from 
Licor (Lincoln, NE).  Boyden chambers for cell invasion were purchased from BD 
Bioscience (San Jose, CA) 
 
5.2.2 Cell viability assay 
H1299 (17,000 cells/well) were seeded onto 96-well plate and after 24 hours the cells 
were treated with serial concentration of polymethoxyflavones and their metabolites.  
After incubation for 24, or 48 hours, the media will be replaced with assay media 
containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)  at 2 
mg/ml (Sigma-Aldrich).  After 0.5-2 hours of incubation at 37°C, the MTT solution will 
be replaced with 100μL/well of DMSO to solubilized remaining reduced formazan dye.  
After gentle mixing, the absorbance will be determined at 570mm with a microtitre plate 
reader (Elx800TM, BioTek Instrument, VT, USA). 
 
77 
 
5.2.3 Wound healing assay 
H1299 human lung cancer cells (4×104 cells) were seeded onto 24-well plate and were 
allowed to grow to confluence.  The cells were washed with PBS and the cell monolayer 
was scraped with 200µl tip to create the gap. The treatment media containing serial 
concentration of PMF and metabolites was added to each well and pictures were taken at 
0, 12, 24, 36 and 48h.  The wound healing percentages were calculated from gap width in 
each timepoint compare to 0 h and the data were shown in confluency (%) of the gap 
area.  At the endpoint of the experiment, wound healing (%) capacity was calculate. 
 
5.2.4 Invasion assay 
The invasion shambers are rehydrated by serum-free RPMI at 37°C for 2 hours.  Prepare 
H1299 cell suspension at a density of 5x104 /ml in serum-free media.  Prepare treatment 
at desired concentration by diluting with DMSO.  Add 750µL of complete media in the 
lower chamber of the transwell.  Add 200µL of cell suspension in the upper champer with 
or without the treatments.  Let incubate for 24 h.  The invaded cell were then fixed with 
Formaldehyde, permiablized with Methanol, and stain with crystal violet.  Remove non-
invading with cotton swap.  Gently place the insert onto glass slide to be photographed 
with invert microscope.  The invaded cells are count by randomly photograph three spot 
on the insert.  The data present as % cell invasion. 
 
5.2.5 Immunoblotting 
Cells were seeded into 15 cm petri dishs.  After 24 hours, the cells were treated with 
serial concentration of PMF and metabolites, and incubate for 72 hours.  Floating cells 
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were collected, cells were washed with ice-cold PBS and then incubate for 10 min on ice 
with lysis buffer supplement with phosphatases and protein inhibitors.  Total protein 
concentrations were quantified by BCA™ protein assay kit, 50-150µg of protein was 
resolved by 8-12% SDS-PAGE and transfer to nitrocellulose membrane.  After blocking 
with blocking buffer (Licor, Lincoln NE)  diluted with PBS, proteins of interest were 
probed using various antibodies at manufacturer’s recommended concentration, then 
probed with florescence secondary antibody.  The protein bands were visualized by 
Odyssey fluorescence reader. 
 
5.2.6 Enzyme-linked immune sorbent assay (ELISA) 
H1299 (25×104) cells were seeded into 6-well plates.  After 24 h, the media was replaced 
with treatment media containing 5HN, M4, M5, M6 and incubate for 24 hours.  The 
media for each well was collected and centrifuged at 2,147 × g, 4°C for 10 minutes.  the 
supernatant was collected and stored at -80°C until ELISA assay are performed.  ELISA 
was done according to manufacturer protocol (R&D system, Minneapolis, MN).  The 
assay was done in duplicate and repeat at least twice. 
 
5.2.7 Determination of intracellular uptake of polymethoxyflavone and metabolites 
in H1299 human lung cancer cells 
H1299 (100×104) cells were suspend in 1 mL of complete media containing serial 
concentration of 5HN, M4, M5 and M6 and incubate at 37°C for 30, 90, 180 and 360 
minutes.  After incubation, cell suspension were centrifuge at 2,147×g at 4°C for 3 
minutes using a bench top Eppendorf centrifuge.  Supernatant was discarded, and the cell 
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pallets were washes twice with 1 mL of ice-cold PBS, then re-suspended in 1mL PBS.  
The cells were sonicated with a probe sonicator for 5 seconds interval, for 3 times.  To 
acquire protein supernatant, the samples were centrifuge at 2,147 × g, 4°C for 15 
minutes.  The supernatant was collected and mixed 1:1 ratio with HPLC-grade methanol 
and stored at 4°C until HPLC analysis. The analysis for determination of PMFs 
compounds was done by reverse phase HPLC with electrochemical (EC) detection 
following protocol that has been developed previously (205).  
 
 
5.3 Result 
5.3.1 PMFs and their metabolites at non-toxic concentration inhibit lung cancer cell 
migration  
 To evaluate the efficacy of PMFs on anti-metastasis we studied   We first 
determine the cytotoxicity of PMFs and their metabolites on H1299 lung cancer cells.  
The MTT assay data shows that NBT and its derivatives (M1, M2, M3) have lower 
toxicity towards H1299, while 5HN and its derivative (M3, M4, M5) have relatively 
higher toxicity (Fig 5.1).   
 According to the cytotoxicity data we choose 25 μM of NBT, M1, M2, M3; 
10μM for 5HN, M5, M6 and 1μM of M4 to test on their ability in inhibiting cancer cell 
migration.  The wound healing assay was performed and the result demonstrates higher 
cell migration inhibitions of 5HN and its metabolites than that of NBT and its 
metabolites.  NBT does not show significant cell migration inhibition, while M1, M2 and 
M3, at 25 μM inhibit 10%, 43%, and 33% of cell migration (Fig 5.2).   
Figure 5.1 Growth inhibitions
cancer cells.  The cells were seed in 96
concentration of (A) NBT, M1, M2, M3; or (B) 5HN, M4, M5, M6.  After 48h 
viability was measured by MTT assay as described in methods. Data were expressed as mean ± 
standard deviation (SD). 
 
Cell migration inhibition of 5HN, M3, M5 at 10 
and 66% respectively.  M2 was the stro
however; compare to 5HN metabolites it still need very high concentration of 50 
show similar level of inhibition (data not shown).
Between 5HN, M4, M5, and M6, M4 show highest migration inhibition in which 
only 1μM of M4 resulted in lower cell migration than that of 5HN, M5, and M6 at 10
The efficacy of M4 is consistent with the data on growth inhibition.  With the higher 
potency of 5HN group over NBT group, we will focus on 5HN, M4, M5, and M6 in 
further investigation of anti
well as cellular uptake. 
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 of nobiletin, 5HN, and their metabolites on H1299 human lung 
-well plates. After 24 h, cells were treated with serial 
µM and M4 at 1 µM are 25%, 49%, 80% 
ngest compounds among NBT metabolites, 
 
-invasion, molecular mechanism of PMFs anti
of treatment cell 
µM to 
μM.  
-metastatic as 
Figure 5.2 Cell migration inhibitions by PMFs and their metabolites.  H1299 human lung cancer 
cells were seed in 24-well plates and allow to
scraped and treated with serial concentration of NBT, M1, M2, M3 (A) or 5HN, M4, M5, M6 (B). 
The pictures were taken at 0, 12, 24, 36 and 48 hours with 40x magnification.  The gap
measured by SPOT program and 
wound healing as relative to non
(48h) picture of control, 5HN, M4 and M5
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 grow to confluence.  The cell monolayer were 
the cell migration percentage was calculated. (C) Shows relative 
-treated cells (control) and (D) represent start (0h) and endpoint 
 
 
s were 
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5.3.2 5HN and its metabolites inhibit H1299 cell invasion in vitro 
 Tumor metastasized by shedding tumor cell population into the tumor blood 
vessels formed during angiogenesis.  These cells travel through the blood stream and 
reach secondary site where they start to invade into a surrounding tissue further away 
from theirs primary tumor location.  To invade, these cells produce several enzymes to 
degrade the extracellular matrix barrier which surround the blood vessel allowing them to 
migrate into the nearby tissue.  We performed Boyden chamber in vitro invasion assay in 
which the layer of matrigel represent the extracellular matrix.  The cell incubated with 
5HN, M4, M5, and M6 show weaker invasion capacity compare to the control group 
indicating that the treatment of PMFs interfere with invasive characteristics of H1299 
cells.  The result indicate M6 at 10μM to be the strongest treatment followed by M5 
(10μM), M4 (1μM), and 5HN (10μM).  The relative inhibition percentage of 5HN, M4, 
M5, and M6 are 18, 38, 47, and 53% respectively.  It should be noted that M4 was use at 
the same concentration that showed the strongest inhibition in the prior experiments; 
however, in Boyden chamber assay, the result does not show superior activity of M4 at 
this concentration.  From the 10x picture taken by SPOT program, the treatment of 5HN 
and metabolites does not show any morphology alteration to H1299 cells, the reduced 
invasion only observed with the decrease in the number of cells invaded after the 
incubation period. 
 
Figure 5.3 Cell Invasion inhibition
chamber of a transwell coated with matrigel with or without 5HN, M4, M5, 
37°C for 24 h with the complete media in the lower chamber as chemo attractant
cell then fixed with formaldehyde and stained with crystal violet.  The picture of the invaded cells 
were taken by inverted microscope 
manually and the data express as relative invasion percentage.
 
5.3.3 5HN and its metabolites modulates 
invasion in H1299 lung cancer cells
 To investigate the mechanism behind the effects of 5HN, M4, M5 and M6 on 
H1299, we investigate the key proteins involved in tumor
tumor metastatic.  We previously show in the earlier chapter that
of 5HN and its metabolites successfully inhibit protein expression of HIF
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 by 5HN and its metabolites. Cell were seeded onto the upper 
or M6 and incubate at 
using a SPOT program at 4x and 10x, the cell were counted 
 
protein involved in cell migration and cell 
 
-induced angiogenesis and 
, in H1299,
 
.  The invaded 
 the treatment 
-1α and reduce 
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protein secretion of VEGF, the main growth factors secreted by cancer cells to activate 
endothelial cell function in tumor angiogenesis process.   
We interested to see in more detail of how 5HN and metabolites interact with 
other protein target in the migration and invasion signaling pathways.  We first studied a 
cytoplasmic tyrosine kinase FAK which is the key regulatory protein in cell migration.  
The treatment of 5HN and metabolites inhibit FAK activation as shown in the decrease 
expression of phosphorylated FAK (pFAK) (Fig 5.4A).  5HN, M4, M5, and M6 decrease 
pFAK by 30, 48, 47, and 65% respectively.  As shown here at 10μM strongest response 
observed in M6 followed by M5 and 5HN, while 1 μM M4 have similar response as 
10μM M5.  FAK regulate cell migration through downstream signaling pathways one of 
which is Src-dependent.  FAK served as a scaffold for Src phosphorylation which in turn 
initiates cell migration.  The treatment of 5HN, M4 (1 μM), M5, and M6 decrease this 
activation of Src-family proteins by 52, 41, 18 and 55% accordingly (Fig 5.4B).  To this 
aspect, FAK together with Src can also induced cell invasion via the activation of 
Endophillin A2, and MT1-MMP; however, our result does not show a consistent 
inhibition of both proteins (data not show). 
Cell invasion can be initiated by the activation of urokinase plasminogen activator 
(uPA) by binding to its receptor urokinase plasminogen activator receptor (uPAR).  The 
treatment of M4 decrease the secretion of uPA protein from H1299 lung cancer cells, 
while the treatment of 5HN, M4, M5, and M6 down regulate protein expression of uPAR.  
1μM M4 is the only compound that is effective in inhibiting uPA secretion, while 5HN, 
M5, and M6 are not effective and in some cases increase uPA secretion (Fig 5.5A).   
Figure 5.4 PMFs down-regulate protein involved in tumor cell migration in H1299 lung cancer 
cells. (A) Immunoblot of pFAK after the treatment of 5HN, M4, M5 and M6.  (B) Immunoblot of 
p-Src family in H1299 cells after treatments with 5HN, M4, M5 and M6.  the total p
wereseperated by 8-12% SDS
with The graph represent the fluorescent density qualified by iStudio program. The experiments 
were repeated for three times. 
mean ± standard deviation (SD).  
 
However, uPAR receptor 
which at similar level ranging from 32
is effective in both markers at a relatively low concentration of 1
Cell invasion also facilitated by the secretion of Matrixmetallo protease enzymes 
(MMPs) which function to degrade collagen, the major component of extra cellular 
matrix, allowing cancer cells to pass
secondary tumor site.  MMP
associated with tumor metastasis and have been use as crucial metastasis markers.  
Herein we studied both MMPs as well as theirs en
discovered that the treatment of 5HN, M4, M5, and M6 decrease the expression of MMP
2, and MMP-9, while increase protein expression of its inhibitors TIMP
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-PAGE.  The protein band were visualized by Odessey Flurometer 
β-actin were used as equal loading controls  The data was shown in 
 
expression is down regulated in 5HN, M4, M5, and M6 all of 
-47% inhibition.  In it crucial to point out that M4 
μM. 
 through the barrier that protect the tissue at the 
-2 and MMP-9 are two major MMPs that have been 
dogenous inhibitors, TIMP
-2 (Fig 5.6).  
 
rotein 
-2.  We 
-
 
Figure 5.5  PMFs down-regulate protein involved in
cells. (A) Protein content of uPA secreted by H1299 after the treatment of 5HN, M4, M5 and M6.  
The cells were seed into 6-well plates with or without treatment of PMFs. The media were 
collected and the secreted VE
mean ± standard deviation (SD).
5HN, M4, M5 and M6 for 48h.  Total protein was seperated by 12% SDS
bands were visualized by Odyssey Imaging system with the graph representing the fluorescent 
density qualified by iStudio program. The experiments were repeated for three times. 
were used as equal loading controls  The data was shown in mean ± standard deviatio
 
10μM of 5HN, M5, M6 and 1
expression (Fig 5.6A) while 0, 41, 57, and 20% of MMP
compared to untreated control.  
which at 10 μM, M5 and M5 show similar inhibition while 5HN is the least effective 
compound.  In addition, 1
concentration, but it is significantly more effective than that of 5HN.  It should be noted 
that the dose dependent inhibition is not significant in the compounds tested.
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 tumor cell invasion in H1299 lung cancer 
GF protein was quatify using ELISA assay.  The data was shown in 
 (B) Immunoblot of uPAR in H1299 cells after treatments with 
-PAGE.  The protein 
μM of M4 inhibits 26, 42, 66 and 52% of MMP
-2 protein expression (Fig 5.6B ) 
The trend in both MMP-2 and MMP-9 are consistent in 
μM M4 is slightly less effective than M5 and M6 at higher 
 
β-actin 
n (SD). 
-9 
 
Figure 5.6  PMFs down-regulate protein involved in tumor cell invasion in H1299 lung cancer 
cells. Immunoblot of MMP9, MMP2, TIMP2 after the treatment of 5HN, M4, M5 and M6 
h. Total protein was seperated by 8
Odessey Flurometer with The graph represent the fluorescent density qualified by iStudio 
program. The experiments were repeated for three times. 
 
The induction of MMPs inhibitor, TIMP
M5 (10 μM) followed by M6 (10 
TIMP-2 expression by 190, 120, 63, and 24% compare to untreated control.  Similar to 
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-12% SDS-PAGE.  The protein band were visualized by 
 
-2, is most potent in the treatment with 
μM), M4(1 μM), and 5HN (10 μM), they increase 
 
for 48 
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the decrease in MMPs expression, an increase in concentration of each compound does 
not show significant different with their lower concentration counterparts. 
 
5.3.4 Intracellular content of 5HN, M4, M5, and M6 partially explain their anti-
angiogenesis and anti-metastasis inhibition on H1299 lung cancer cells 
Bioavailability is an important part of functional compound effectiveness.  To 
evaluate how much of the PMFs were incorporate into the cells, we utilized HPLC to 
detect intracellular uptake of each compounds.  The experiment was done at 30, 180 and 
360 minutes time points with 5HN, M4, M5 and M6 at the same concentrations of 1 μM.  
The cell were collected and lysed by sonication, the compounds were retrieved by 
methanol extraction.  The sample were then subject to reverse phase HPLC method 
develop previously (205) to detect 5HN, M4, M5 and M6.  We also use enzymatic 
treatment to release free PMFs from any conjugated form that maybe presented in the 
samples.  In the enzyme treated group (Fig 5.7A), all of the compounds were readily 
uptake into the cells as indicate by a spike at 30 minute time point.  At 180 minutes, 5HN 
level increases and remains at similar level until 360 minutes.  M4 level at 180 minutes is 
similar to M4 at 30 minutes, its level increases at 360 minutes.  Despite a slight drop of 
M5 level at 180 minute, M5 level remain the highest in all of the compounds as its level 
increases at 360 minute time point.  The level of M6 decreases since the spike at 30 
minutes and continue to decrease until it reach almost zero at 360 minute.  It should be 
noted that, we also detected M4 and M5 in the M6 samples in which M4 level remain 
somewhat constant after the spike at 30 minutes until 360 minutes and the level of M5 
increase constantly.  The 
the enzyme treated one (Fig 5.7B)
 
Figure 5.7 Intracellular levels of 5HN, M4, M5 and M6 in H1299 human NSCLC cells.  H1299 
were incubated with 5HN, M4, M5 and M6 for 30,
treatmnets. The cells were seed into glass tube with or
were collected, lysed and the compounds were retrieved by methanol extraction.  
intracellular concentrations of compounds were q
protocol previously described 
M5, and M6 at each timepoint 
represent area under the curve calculate from intracellular uptake data in the 
represent mean ±SD (N=3).
 
 Areas under the curve (AUC) were calculated from summation of total 
intracellular uptake at each time
89 
 
result in non-enzyme treated group show similar trend to that of 
.  
 180 and 360 min with or without enzymatic 
 wih various treatment of PMFs.  
uantified by reverse phase HPLC follow the 
(A) the graph represent intracellular concentration of 5HN, M4, 
with enzymatic treatment (A) or without (B), the bar chart 
top 
 
 point and the result was shown in Fig 5.7C
 
the cell 
The 
(C) 
panel.  All data 
.  For the 
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length of the experiment (6h), intracellular uptake of M5 was the highest, followed by 
5HN and M4.  In enzyme treated group, total amount of M5, 5HN M4, and M6 were 897, 
755, 552 and 271 μmol/106 cells×minute.  As for non-enzyme treated group the level was 
956, 546, 478, and 225 μmol/106 cells×minute.  Except of M5, the total intracellular 
uptake of the compounds in enzyme treated group are higher than that of non-enzyme 
treated group as expected; however, the differences are not statistically significant. 
The cellular uptakes were shown to be dose dependent (data not shown) as for all the 
compounds higher concentration result in higher intracellular level. 
 
 
5.4 Discussion 
 We have shown that nobiletin, 5HN and their metabolites are effective inhibiting 
endothelial functions which are a crucial component in angiogenesis.  
Polymethoxylatedflavones, have been shown to be effective towards cancer inhibition.  
This study is the first study to explore PMFs activities as anti-angiogenic agents. 
Nobiletin and tangeretin have been shown to be active in both in endothelial cells as well 
as in cancer cells; however, their metabolites have not been study in the aspect of anti-
metastatic activities.  Herein, we investigate the activities of PMF metabolites compare to 
their parents compounds in cancer cell migration, invasion and possible molecular 
targets. 
In H1299 cell growth inhibition, the compounds with hydroxylation were shown 
to be stronger in growth inhibition as well as cancer cell migration and additional 
hydroxylations to 5HN structure enhance their activities.  Despite some migration 
91 
 
inhibition gain from the treatment of NBT metabolites (M1, M2, and M3)  the 
concentration needed to see the effect is still higher than that of 5HN metabolites, 
therefore we choose to focus on the latter group of compound.  Similar to the result in the 
previous chapter, M4 remain the strongest compound among 5HN metabolites in cell 
migration inhibition, this highlight the importance of two hydroxylated group on M4 
structure.  M6 is the second strongest compound in cell migration inhibition it is 
significantly more effective than M5 and 5HN.  Both M4 and M6 which are highly 
effective in cell migration inhibition also shown to successfully inhibit the upstream 
proteins which regulates cell migration: pFAK and pSrc.  In comparison M5 and 5HN 
which is less effective in cell migration inhibition show to be less effective in down 
regulating both proteins.  Thus the migration data can be explained partially by the 
inhibition of these protein markers. 
 In Boyden chamber invasion assay, the same treatment of 5HN and metabolites 
(10µM for 5HN, M5, M6 and 1µM M4) result in different trend among the compound.  
M6 which has three hydroxylated group result in highest invasion inhibition followed my 
M5, M4 and 5HN.  This can be due to the fact that cell migration and cell invasion are 
triggered by different mechanism and that these compound target different proteins.  
uPA/uPAR system is one of the main cell invasion markers which got activated in the 
cancer cells (206).  The treatment of M4, but not the other compounds, decreases the 
secretion of the ligand uPA.  On the other hand its receptor is down regulated by 
compounds in 5HN group at different level.  According to this data M4 can represent a 
candidate for anti-angiogenesis/anti-metastasis as a single compound.   In addition, we 
studied MMPs which represent another major target in cell invasion.  They are the main 
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enzyme utilized by the cancer cells to degrade extracellular matrix allowing cells to 
invade into surrounding tissue.  Our experiments show consistent trend of MMPs 
inhibition as well as TIMP-2, MMP inhibitor, induction.  Interestingly, M6 shows the 
strongest MMPs inhibition, while M5 shows the highest TIMP-2 induction.  This pattern 
coordinates very well with the cell invasion data from the Boyden chamber assay.    
Altogether, the molecular data point out that 5HN and its metabolite target multiple 
pathways in cell migration and cell invasion.  And that targeting multiple protein targets 
will result in effective anti-metastasis outcomes 
 An important finding in all the anti-metastasis experiments shown here is that M4 
is identified to be a high potency compound which is very effective toward inhibition of 
cancer cell metastasis process.  In migration assay 1μM of M4 is the strongest treatment 
in the study, this trend carried through the modulation of cell migration initiation protein 
pFAK/pSrc.  In this data set, even though the difference is not as clear as demonstrate in 
cellular migration assay, in relative comparison only 1μM of M4 is needed to observed 
the inhibition of protein activation while other compound show inhibition at the 
concentration that is ten times higher.   As for inhibition of cell invasion, % cell invasion 
inhibitions per µM are 1.9%, 38%, 4.7%, and 5.3% for 5HN, M4, M5 and M6 
respectively.  This shows stronger anti-invasion capacity of M4 which also presented in 
the inhibition of uPA/uPAR protein secretion/expression.  The inhibition of MMPs 
enzymes and induction of MMP inhibitor per micro molar of treatment can be ranked as 
M4 > M5≈ M6 >5HN in all of the markers studied.  M4 is 5-10 times more effective than 
other compound in this group.  This substantiates a high potency of M4 as anti-metastatic 
agent as well as anti-angiogenic agent as observed in previous chapter.   
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An uptake experiment reveals that 5HN was rapidly absorbed into the cells and 
the intracellular level decrease over time.  On the other hand, M4 and M5 showing 
similar trend that the compounds were absorbed quickly and the levels are increasing 
over time.  During the time of the experiment, intracellular level of the four compound 
can be ranked as M5>5HN>M4>M6.  The higher intracellular content of M5 can explain 
their effectiveness in inhibiting MMPs protein expression and TIMP-2 induction.  
Although, M6 is shown to be very effective in inhibiting cell invasion and down regulate 
MMP-2 and MMP-9 expression and moderately induce TIMP-2, its intracellular level is 
relatively low compare to other compounds.  In M6 sample however, significant amount 
of M4 and M5 were detected and they are increasing after 3 h.  This maybe a result of 
cell metabolism as observed in previous study reporting that PMF can be metabolized 
within the cancer cells (207).  If this is the case, the effects observed with M6 treatment 
may be the result of conversion products, M4 and M5, in addition to the direct effects of 
M6.  M4 intracellular content is lower than that of 5HN and M5; however, its effective 
concentration is ten times lower than that of other compounds, so the low bioavailability 
might not have significant effects in anti-metastasis of M4.  The paradox trend of M4 and 
M6 demonstrate that in addition to cellular uptake other factors such as compound 
lipophilicity, specific targets, half-life and their metabolism also involve in the efficacy of 
their inhibitory effects. 
It should be highlighted that we studied 5HN and metabolites as a component of 
food.  This means that the compound will be delivered via oral intake in which 5HN will 
be metabolites and turn into M4, M5 and M6.  All the data presented suggested that each 
compound in this group target different protein with different magnitude, while the 
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intracellular content information reveal the difference of how each compounds get 
incorporated into the cells.  All in all, the compounds in 5HN group show different 
strength in term of anti-metastasis suggestingthe combination of these compounds will 
potentially result in highly effective anti-angiogenesis/anti-metastasis agents.  This work 
demonstrates PMFs and metabolites, especially 5HN and metabolite as good candidates 
for anti-angiogenic/ anti-metastatic diet regime.  They are effective both in endothelial 
cells model as well as human lung cancer cells model.  Different PMFs target different 
steps in angiogenesis/ metastasis process.  Some prevent the process of angiogenesis 
partly by interfering with VEGF/VEGFR axis of signal transduction.  Others down 
regulate the expression of MMP-2 and MMP-9, key enzymes required for degrading 
extracellular matrix that will enable cellular movements in the metastasis process.  The 
position and number of hydroxylation was shown to be essential in PMFs anti-
angiogenesis/metastasis activities, thus the structure manipulation may be useful in 
enhancing their bioactivities as well as their bioavailability. 
 
 
 
 
 
 
 
 
 
95 
 
CHAPTER 6 
CONCLUDING REMARKS 
 Since the beginning of anti-angiogenic research in 1970’s, several angiogenic 
compounds has been identified and approved by the FDA to be used as adjuvant therapy 
for cancer treatments.  The success of Bevacizumab in prolonging the survival of 
colorectal cancer patients made angiogenesis therapy becomes the “fourth modality for 
cancer treatment” as declaired by Mark McClellan in 2004.  The discovery of anti-
angiogenic agents have been focusing on monoclonal antibodies, small molecule tyrosine 
kinase inhibitors and mTOR inhibitors most of which targeted a very specific protein 
target.  They are highly effective for treatments but at the same time can cause severe 
side effects of not used properly.  For example, VEGF inhibitors can induce hypertension 
and must be applied in conjugate with vasodilation agents (208).  In addition, Cytotoxic 
drug start to gain attention as anti-angiogenic agents when used at low concentration 
(196).  The effectiveness of combination treatment between anti-angiogenic drug and 
chemotherapy was shown in the treatment of NSCLC patients with Bevacizumab and 
paclitaxel in which the treatments significantly prolong survival in NSCLC patients.  At 
present,  
 In addition to the discovery of anti-angiogenic agent for cancer treatment 
regimen, the notion of angioprevention also arise in which functional components in 
food, when administered regularly, may inhibit tumor from recruiting blood vessel and 
preventing them from metastasizing.  Several bioactive compounds, including 
polymethoxylated flavones and its metabolites, have been shown to possess anti-cancer 
activities.  Natural compounds are relatively low toxic and have multi-target actions 
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which help reduce the likely chance of developing severe side effects.  Our studied reveal 
the efficacy of 5HN and metabolites (M4, M5 and M6) as both anti-angiogenic and anti-
metastasis compounds.  In particular M4 administered at a very low concentration is 
effective in both endothelial cells model and non-small cell lung cancer model indicating 
a positive systematic effects in term of antiangiogenic/antimetastatic actions.  Each 
compound in this group appeared to target slightly different markers at different 
magnitude as well as they have different capacity to be incorporated into the cells.  All of 
the evidence indicates that 5HN, M4, M5 and M6 can be perceived as a good system for 
anti-angiogenesis/anti-metastasis regimen.  If 5HN were administered orally and was 
allowed to metabolized in the body to create M4, M5 and M6, the efficacy of anti-
angiogenesis/anti-metastasis effects will result from the combination effects of all of 
these compounds which could be significantly stronger and safer than application of 
single compound at high dose.  Therefore, it is safe to state that PMFs is a promising 
angiopreventative agent derived from food which can be incorporate into medical diet 
regimen design to prevent abnormal angiogenesis.  More studied is needed in term of 
investigating PMFs effect in the in vivo setting as well as clinical setting to substantiate 
their actions as appropriate anti-angiogenesis and anti-metastasis agents. 
 The research presented here highlights the possibility of functional ingredients 
derived from food sources and their endless applications to health.  At present, when the 
field of medicine and nutrition are starting to embrace each other, research in functional 
ingredients, their activities and applications are increasing exponentially.  Most if not all 
sectors including the academia, the industry, the regulatory sectors as well as health care 
professionals realized the important of food in addition to its basic nutrition and are 
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utilizing food to it best advantage.  This study will facilitate such purpose by add on the 
information needed in utilizing food to support health and wellness.  
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